Welcome to Needham

Needham & Company, LLC, a subsidiary of The Needham Group, Inc., is a nationally recognized investment banking and asset management firm focused solely on growth companies and their investors. Needham’s mission is to provide its clients with the long-term advice they need to achieve their business goals. The Firm's commitment to exceptional service is unusual in today’s business climate, and is born of a tradition which stresses integrity above all else. We strive to be front of mind, approachable and idea driven. Needham is actively engaged in the public and private capital markets, boasting a 32-year track record of executing complex transactions and the accompanying reputation for excellence in our markets.

Needham’s principal activities involve assisting our clients through a variety of advisory and transaction-related services, with a specific focus on:

 

To check the background of our Firm on FINRA’s BrokerCheck , click here



  • Esperion Therapeutics, Inc. (NASDAQ: ESPR) is the Lipid Management Company passionately committed to developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated LDL-C. Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced lipid management team at Esperion is committed to developing new LDL-C lowering therapies that will make a substantial impact on reducing global cardiovascular disease; the leading cause of death around the world. Bempedoic acid and the company's lead product candidate, the bempedoic acid / ezetimibe combination, are targeted therapies that have been shown to significantly reduce elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. For more information, please visit www.esperion.com

    Esperion Therapeutics, Inc. raised $151.9 million in its follow-on offering at $49.00 per share. Needham acted as co-manager on the transaction. Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to continue to fund the CLEAR Outcomes cardiovascular outcomes trial for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia, or who are at high risk for cardiovascular disease, and who are only able to tolerate less than the lowest approved daily starting doses of a statin and can be considered statin intolerant; support the New Drug Application and Marketing Authorization Application submission activities and its operations through regulatory approvals for LDL-C lowering indications for the bempedoic acid / ezetimibe combination pill and bempedoic acid; support pre-commercial launch activities for the bempedoic acid / ezetimibe combination pill and bempedoic acid; initiate development activities for a reformulated tablet of bempedoic acid for nonalcoholic steatohepatitis (NASH) indications; and for working capital and general corporate and administrative expenses.

  • Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL; Nasdaq Global Select Market: ZEAL) is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand is based in Copenhagen (Glostrup), Denmark.

    Zealand Pharma A/S raised $89.1 million in its initial public offering of American Depository Shares at $17.87 per share. Needham acted as a co-lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 656,250 ADSs at the initial public offering price to cover over-allotments.

  • Perfect Commerce provides world-class sourcing and procurement solutions to the enterprise and public market sectors. Automating spend management initiatives since 1994, Perfect offers a true end-to-end platform that enables businesses to reduce costs while increasing operational efficiency. The Perfect Suite of software and services solves complex industry challenges, throughout the spend lifecycle.

    Perfect Commerce, a leading SaaS-based provider of end-to-end procurement solutions, today announced that it has completed its reverse takeover by PROACTIS Holdings (LON: PHD), a global Spend Control and eProcurement solution provider, will pay $127.5 million at completion in cash and through the issue of a $5.0 million convertible acquisition loan note, and up to a further $5.0 million in cash upon the occurrence of specified events during the period to July 31, 2018. Needham & Company acted as exclusive financial advisor to Perfect Commerce LLC.

  • Ichor Holdings, Ltd. (NASDAQ: ICHR) is a leader in the design, engineering and manufacturing of critical fluid delivery subsystems for semiconductor capital equipment. Our primary offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. Our gas delivery subsystems deliver, monitor and control precise quantities of the specialized gases used in semiconductor manufacturing processes such as etch and deposition. Our chemical delivery subsystems precisely blend and dispense the reactive liquid chemistries used in semiconductor manufacturing processes such as electroplating and cleaning. We also manufacture certain components for internal use in fluid delivery systems and for direct sales to our customers. This vertically integrated portion of our business is primarily focused on metal and plastic parts that are used in gas and chemical systems, respectively.

    Ichor Holdings, Ltd. raised $122.2 million in its follow-on offering at $19.32 per share by selling shareholders. Needham acted as passive bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 825,000 shares of common stock at the follow-on offering price to cover over-allotments. Ichor Holdings, Ltd. will not receive any proceeds from the offering.

  • ViXS Systems (TSX: VXS) is a pioneer and market leader in designing revolutionary media processing semiconductor solutions for video over IP streaming solutions, with more than 470 patents issued and pending worldwide, numerous industry awards for innovation, and over 33 million media processors shipped to date. ViXS is driving the transition to Ultra HD 4K across the entire content value chain by providing professional and consumer grade chipsets that support the new High Efficiency Video Coding (HEVC) standard up to Main 12 Profile, reducing bandwidth consumption by 50% while providing the depth of color and image clarity needed to take advantage of higher-resolution content. ViXS’ XCodePro 300 family is ideal for Ultra HD 4K infrastructure equipment, and the XCode 6000 family of system-on-chip (SoC) products achieve unprecedented levels of integration that enable manufacturers to create cost-effective consumer entertainment devices. ViXS is headquartered in Toronto, Canada with offices in Europe, Asia and North America. VIXS™, the ViXS® logo, XCode®, XCodePro™ and Xtensiv™ are trademarks and/or registered trademarks of ViXS. Other trademarks are the property of their respective owners.

    ViXS Systems (TSX: VXS), a pioneer and leader in media processing solutions, today announced that it has sold its legacy MoCA (Multimedia over Coaxial Alliance) business to Pixelworks (NASDAQ: PXLW), a provider of visual processing solutions, in an in an all-stock transaction valued at $20.2 million. Needham & Company acted as exclusive financial advisor to ViXS Systems.

  • Regulus Therapeutics Inc. is a biopharmaceutical company developing innovative medicines targeting microRNAs. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Regulus maintains its corporate headquarters in La Jolla, CA.

    Regulus Therapeutics, Inc. raised $46.0 million in its follow-on offering at $0.91 per share. Needham acted as co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 6,600,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering together with other available funds, will be used by Alder Regulus Therapeutics Inc. to fund clinical development of its clinical candidates, RG-012 and RGLS4326, development of its earlier microRNA development candidates and programs, for the identification and validation of additional microRNA targets, and for capital expenditures, working capital and general corporate purposes.

  • Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), is a clinical-stage biopharmaceutical company committed to transforming the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions. Leveraging its pioneering monoclonal antibody technologies, Alder discovers and develops novel therapeutic antibodies designed to deliver highly differentiated, best-in-class clinical profiles. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody administered quarterly via infusion that allows for 100% of the dose available to selectively and potently inhibit the calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.

    Alder Biopharmaceuticals, Inc. raised $172.5 million in its follow-on offering at $10.00 per share. Needham acted as co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,250,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering together with other available funds, will be used by Alder Biopharmaceuticals, Inc. to fund the continued development of eptinezumab, including completion of the ongoing infusion pivotal trial program, the planned submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), establishment of the commercial drug supply chain and other commercialization activities, and for working capital and general corporate purposes.

  • Tintri, Inc. (NASDAQ: TNTR) offers an enterprise cloud infrastructure built on a public cloud-like web services architecture and RESTful APIs. Organizations use Tintri all-flash storage with scale-out and automation as a foundation for their own clouds—to build agile development environments for cloud native applications and to run mission critical enterprise applications. Tintri enables users to guarantee the performance of their applications, automate common IT tasks to reduce operating expenses, troubleshoot across their infrastructure, and predict an organization’s needs to scale—the underpinnings of a modern data center. That’s why leading cloud service providers and enterprises, including Comcast, Chevron, NASA, Toyota, United Healthcare and 21 of the Fortune 100 companies, trust Tintri with enterprise cloud.

    Tintri, Inc. raised $67.0 million in its initial public offering at $7.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 1,000,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Tintri, Inc. for general corporate purposes including working capital, product development and operating expenses. Furthermore, the Company may use a portion of the net proceeds from this offering to repay outstanding indebtedness, including indebtedness under our loan and security agreements with SVB and TriplePoint.

  • Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia's lead product candidate, vadadustat, is an oral, investigational therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing.

    Akebia Therapeutics, Inc. raised $66.7 million in its follow-on offering at $14.50 per share. Needham acted as senior co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 600,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. for for the continued clinical development of vadadustat, including adding manufacturing capabilities; for clinical development of AKB-5169; for discovery, research and preclinical studies of our other product candidates; and the remainder for working capital, business development and other general corporate purposes.

  • Blue Apron Holdings, Inc. (NASDAQ: APRN) has a mission to make incredible home cooking accessible to everyone. Launched in 2012, Blue Apron is reimagining the way that food is produced, distributed, and consumed, and as a result, building a better food system that benefits consumers, food producers, and the planet. The company has developed an integrated ecosystem that enables the company to work in a direct, coordinated manner with farmers and artisans to deliver high-quality products to customers nationwide at compelling values. Blue Apron’s current products include Blue Apron Meals, Blue Apron Wine, the Blue Apron Market, and BN Ranch, a premium supplier of grass-fed beef and pasture-raised poultry.

    Blue Apron Holdings, Inc. raised $300.0 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by Blue Apron Holdings, Inc. for working capital, capital expenditures and general corporate purposes.

  • Nor-Cal Products Inc. ("Nor-Cal"), is a leading manufacturer of premium-quality vacuum components, chambers and valves for international customers in the fields of semiconductors, coating and displays as well as for leading universities and research facilitiesFounded in 1962 in Yreka, California, USA, Nor-Cal operates plants at its Yreka headquarters and in Ho-Chi-Minh-City, Vietnam, which will further improve the group's global production footprint. In recent years, the company has benefited greatly from its persistent focus on customers in the semiconductor industry and this segment's comparatively high growth. Nor-Cal has identified the medical engineering sector in North America as another very interesting future growth market.

    Nor-Cal Products Inc. ("Nor-Cal"), a leading manufacturer of premium-quality vacuum components, chambers and valves for international customers in the fields of semiconductors, coating and displays as well as for leading universities and research facilities, completed its previously announced sale to Pfeiffer Vacuum Technology AG (ETR: PFV), for $68 million in cash. Needham & Company acted as a financial advisor to Nor-Cal.

  • WageWorks, Inc. (NYSE: WAGE) is a leader in administering Consumer-Directed Benefits (CDBs). WageWorks is solely dedicated to administering CDBs, including pre-tax spending accounts, such as Health Savings Accounts (HSAs), health and dependent care Flexible Spending Accounts (FSAs), Health Reimbursement Arrangements (HRAs), as well as Commuter Benefit Services, including transit and parking programs, wellness programs, COBRA, and other employee benefits. WageWorks makes it easier to understand and take advantage of Consumer-Directed Benefits for more than 100,000 employers and approximately 6.5 million people. WageWorks is headquartered in San Mateo, California, with offices in major locations throughout the United States. For more information, visit www.wageworks.com.

    WageWorks, Inc. raised $173.1 million in its follow-on offering of 1,954,852 Primary and 545,148 Secondary Shares at $69.25 per share. Needham acted as a co-manager on the transaction. The net proceeds from the primary portion of the offering will be used by WageWorks, Inc. for general corporate purposes, including strategic acquisitions, channel partner arrangements, capital expenditures and operating costs. WageWorks, Inc. will not receive any proceeds from the sale of shares by the selling stockholders.

  • Adesto Technologies (NASDAQ:IOTS) is a leading provider of application-specific, ultra-low power, smart non-volatile memory products. The company has designed and built a portfolio of innovative products with intelligent features to conserve energy and enhance performance, including Fusion Serial Flash, DataFlash®, EcoXiP™ and products based on its trademark resistive RAM technology called Conductive Bridging RAM (CBRAM®). CBRAM® is a breakthrough technology platform that enables 100 times less energy consumption than today’s flash memory technologies as well as delivering enhanced performance.

    Adesto Technologies Corporation raised $20.0 million in its follow-on offering at $4.00 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 625,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Adesto Technologies Corporation for general corporate purposes.

  • Crisp Mobile has over 15 years’ experience in delivering marketer content via mobile devices. Crisp’s exclusive focus on the Retail and CPG markets means that only Crisp has both the deep vertical knowledge and the proven ability to activate shoppers on the device they use most often: their mobile phone. Crisp provides the industry’s first end-to-end mobile customer activation platform to deliver radically improved mobile experiences for shoppers and marketers alike. These unrivaled experiences, along with a proven ability to deliver results, have made Crisp a trusted partner to many of today’s largest retail and CPG brands.

    Crisp Mobile, a mobile marketing and advertising company primarily serving CPG and retail customers, completed its previously announced sale to Quotient Technology Inc. (NYSE:QUOT), a leading digital promotions, media and analytics company that connects brands, retailers and shoppers, for approximately $57.5 million. While Crisp will continue to operate as its own brand, Quotient will take advantage of the natural synergies as Quotient expands their efforts in shopper marketing. Needham & Company acted as exclusive financial advisor to Crisp Mobile.

  • Upland Software, Inc. (NASDAQ: UPLD) is a leading provider of cloud-based Enterprise Work Management software. Its family of applications enables users to manage their projects, professional workforce, and IT investments; automate document-intensive business processes; and effectively engage with their customers, prospects, and community via the web and mobile technologies. With more than 2,500 customers and over 250,000 users around the world, Upland solutions help customers run their operations smoothly, adapt to change quickly, and achieve better results every day.

    Upland Software, Inc. raised $46.0 million in its upsized follow-on offering at $21.50 per share. Needham acted as joint bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 279,069 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Upland Software, Inc. for general corporate purposes. General corporate purposes may include additions to working capital, financing of capital expenditures, repayment or redemption of existing indebtedness, repurchases of stock, and future acquisitions and strategic investment opportunities.

  • LendingTree, Inc. (NASDAQ: TREE) operates the nation's leading online loan marketplace and provides consumers with an array of online tools and information to help them find the best loans for their needs. LendingTree's online marketplace connects consumers with multiple lenders that compete for their business, empowering consumers as they comparison-shop across a full suite of loans and credit-based offerings. Since its inception, LendingTree has facilitated more than 65 million loan requests. LendingTree provides access to its network of over 500 lenders offering home loans, home equity loans/lines of credit, reverse mortgages, personal loans, auto loans, small business loans, credit cards, student loans and more. LendingTree, Inc. is headquartered in Charlotte, NC and maintains operations solely in the United States.

    LendingTree, Inc. issued $300.0 million convertible senior notes due 2022 (the "Notes") in an upsized private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The underwriters fully exercised their option to purchase an additional $35.00 million in aggregate principal amount of the Notes to cover overallotments. Needham & Company acted as a co-manager for this transaction. LendingTree, Inc. intends to use the net proceeds from the Notes offering for general corporate purposes including, but not limited to, working capital and potential acquisitions.

  • Corium International, Inc. (NASDAQ: CORI) is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company’s broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer’s disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Endo Pharmaceuticals and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company’s late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being developed with other partners.

    Corium International, Inc. raised $40.3 million in its upsized follow-on offering at $6.25 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 840,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Corium International, Inc. to offering for product development and general corporate purposes, which may include funding research and development, increasing its working capital, reducing indebtedness, acquisitions or investments in businesses, products or technologies that are complementary to its own and capital expenditures.

  • Albireo Pharma, Inc. (NASDAQ: ALBO) is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 3 product candidates and one Phase 2 product candidate. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden.

    Albireo Pharma, Inc. raised $51.9 million in its upsized follow-on offering at $20.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 330,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Albireo Pharma, Inc. to complete the Phase 3 clinical program of A4250 to treat patients with PFIC; to initiate a clinical trial of A4250 in one or more additional pediatric cholestatic liver diseases; to initiate a Phase 2 clinical trial of A3384 to treat BAM; to advance our preclinical program in NASH and, if the company select a product candidate from their NASH program for clinical development, to complete the preclinical development activities necessary to initiate a Phase 1 clinical trial of the product candidate; and for general corporate purposes.

  • SMART Global Holdings (NASDAQ: SGH), the parent company of SMART Modular Technologies, Inc., is a global leader in specialty memory solutions, serving the electronics industry for over 25 years and holds a leading, international, market position, as measured by revenue, in specialty memory.

    SMART Global Holdings, Inc. raised $67.05 million in its initial public offering at $11.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 795,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by SMART Global Holdings, Inc. to repay a portion of their outstanding term loans under the Senior Secured Credit Agreement. In addition, the company intends to use $4.7 million of the net proceeds to make a payment to affiliates of Silver Lake for unpaid management fees in respect of past periods under the Amended and Restated Transaction and Management Fee Agreement, which they intend to terminate upon the completion of this offering. The remaining net proceeds shall be used for general corporate purposes.

  • The Trade Desk, Inc. (NASDAQ:TTD) is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize more expressive data-driven digital advertising campaigns across ad formats, including display, video, audio, native and, social, on a multitude of devices, such as computers, mobile devices, and connected TV. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across the United States, Europe, and Asia.

    The Trade Desk, Inc. raised $252.0 million in its upsized follow-on offering at $52.0 per share of Class A common stock by certain selling stockholders . Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 530,148 shares of Class A common stock at the follow-on offering price to cover over-allotments. The Trade Desk will not receive any proceeds from the offering.

  • G1 Therapeutics, Inc. (NASDAQ: GTHX) is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is based in Research Triangle Park, NC.

    G1 Therapeutics, Inc. raised $116.72 million in its upsized initial public offering at $15.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 781,564 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by G1 Therapeutics, Inc. to advance the product development of trilaciclib, G1T38 & G1T48 and general corporate purposes including working capital and operating expenses.

  • Concurrent Computer Corporation (NASDAQ:CCUR) is a global software and solutions company that develops advanced applications focused on storing, protecting, transforming, and delivering high value media assets. We serve industries and customers that demand uncompromising performance, reliability and flexibility to gain a competitive edge, drive meaningful growth and confidently deliver best-in-class solutions that enrich the lives of millions of people around the world every day. Offices are located in North America, Europe and Asia.

    Concurrent Computer Corporation (NASDAQ: CCUR), a global software and solutions company that develops advanced applications focused on storing, protecting, transforming, and delivering high value media assets, completed its previously announced sale of its Real-Time business segment to Battery Ventures for $35 million in cash. The Real-Time business segment will operate as an independent, privately-held company doing business as Concurrent Real-Time, Inc. Needham & Company acted as financial advisor to Concurrent Computer Corporation.

  • Dermira, Inc. (NASDAQ: DERM) is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s product pipeline includes three Phase 3 product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate, in development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; and olumacostat glasaretil, in development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. issued $287.5 million aggregate principal amount of 3.00% Convertible Senior Notes due 2022 (the “notes”) in a private offering to qualified institutional buyers pursuant to the Securities Act of 1933, as amended (the “Securities Act”). The underwriters fully exercised their option to purchase an additional $37.5 million in aggregate principal amount of the Notes to cover overallotments. Needham & Company acted as a co-manager for this transaction. Dermira intends to use the net proceeds that it receives from the note offering for working capital, capital expenditures and other general corporate purposes. Dermira may also use a portion of the net proceeds from this offering to expand its business by in-licensing or acquiring, as the case may be, product candidates, technologies, compounds, other assets, commercial products or complementary businesses.

  • Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has licensed intellectual property from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven is a company organized under the laws of the British Virgin Islands and its United States operations are based in New Haven, Connecticut.

    Biohaven Pharmaceuticals Holding Company Ltd. raised $193.5 million in its initial public offering at $17.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,485,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Biohaven Pharmaceuticals to initiate and complete two Phase 3 clinical trials of rimegepant for the acute treatment of migraine; fund continued research and development of BHV-3500 for the prevention of chronic and episodic migraine; complete ongoing Phase 2/3 trial of trigriluzole for the treatment of SCA; fund continued research and development of BHV-5000 for the treatment of breathing irregularities associated with Rett syndrome, including completion of planned Phase 1 clinical trial for this indication; repay aggregate indebtedness under credit agreement with Wells Fargo and notes payable to related parties; satisfy remaining obligation to purchase shares of capital stock of Kleo Pharmaceuticals; and fund other research and development activities, including the development of BHV-0223 for the treatment of ALS, as well as for working capital and other general corporate purposes, including the satisfaction of any milestone payment obligations under license agreements.

  • Ichor Holdings, Ltd. (NASDAQ: ICHR) is a leader in the design, engineering and manufacturing of critical fluid delivery subsystems for semiconductor capital equipment. Our primary offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. Our gas delivery subsystems deliver, monitor and control precise quantities of the specialized gases used in semiconductor manufacturing processes such as etch and deposition. Our chemical delivery subsystems precisely blend and dispense the reactive liquid chemistries used in semiconductor manufacturing processes such as electroplating and cleaning. We also manufacture certain components for internal use in fluid delivery systems and for direct sales to our customers. This vertically integrated portion of our business is primarily focused on metal and plastic parts that are used in gas and chemical systems, respectively.

    Ichor Holdings, Ltd. raised $115.2 million in its upsized follow-on offering at $19.50 per share by selling shareholders. Needham acted as passive bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 770,538 shares of common stock at the follow-on offering price to cover over-allotments. Ichor Holdings, Ltd. will not receive any proceeds from the offering.

  • Flexion Therapeutics, Inc. (NASDAQ: FLXN) is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis ("OA"). Flexion's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive intra-articular injections for knee OA annually.

    Flexion Therapeutics, Inc. issued $201.3 million 3.375% convertible senior notes due 2024 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The underwriters fully exercised their option to purchase an additional $26.25 million in aggregate principal amount of the Notes to cover overallotments. Needham & Company acted as a co-manager for this transaction. Flexion intends to use the net proceeds from the Notes offering for the commercialization and manufacture of ZilrettaTM (also known as FX006), if approved, product pipeline development, as well as working capital and general corporate purposes. Flexion may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses, technologies, products or assets.

  • ViXS Systems (TSX: VXS) is a pioneer and market leader in designing revolutionary media processing semiconductor solutions for video over IP streaming solutions, with more than 470 patents issued and pending worldwide, numerous industry awards for innovation, and over 33 million media processors shipped to date. ViXS is driving the transition to Ultra HD 4K across the entire content value chain by providing professional and consumer grade chipsets that support the new High Efficiency Video Coding (HEVC) standard up to Main 12 Profile, reducing bandwidth consumption by 50% while providing the depth of color and image clarity needed to take advantage of higher-resolution content. ViXS’ XCodePro 300 family is ideal for Ultra HD 4K infrastructure equipment, and the XCode 6000 family of system-on-chip (SoC) products achieve unprecedented levels of integration that enable manufacturers to create cost-effective consumer entertainment devices. ViXS is headquartered in Toronto, Canada with offices in Europe, Asia and North America. VIXS™, the ViXS® logo, XCode®, XCodePro™ and Xtensiv™ are trademarks and/or registered trademarks of ViXS. Other trademarks are the property of their respective owners.

    ViXS Systems (TSX: VXS), a pioneer and leader in media processing solutions, today announced that it has sold its legacy MoCA (Multimedia over Coaxial Alliance) business to MaxLinear, Inc. (NYSE:MXL), a leading provider of radio frequency (RF) and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, data center, metro, long-haul fiber networks, and wireless infrastructure. This divestiture will allow ViXS to focus on its core video business strategies, built around delivering best-in-class UHD/HDR solutions for the Consumer and Video Delivery market segments. ViXS plans to use the sale proceeds to improve its balance sheet and for working capital needed to support customers to achieve profitable growth. Needham & Company acted as exclusive financial advisor to ViXS Systems.

  • Synacor (Nasdaq: SYNC) is the trusted technology development, multiplatform services and revenue partner for video, internet and communications providers, device manufacturers, and enterprises. Synacor’s mission is to enable its customers to better engage with their consumers. Its customers use Synacor’s technology platforms and services to scale their businesses and extend their subscriber relationships. Synacor delivers managed portals, advertising solutions, email and collaboration platforms, end-to-end video solutions and cloud-based identity management.

    Synacor, Inc. raised $21.7 million in its follow-on offering at $3.50 per share. Needham acted as joint bookrunner on the transaction. The Company’s underwriters exercised their option to purchase an additional 427,846 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Synacor, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate an organization’s operational response to critical events in order to keep people safe and businesses running. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events such as IT outages or cyber-attacks, over 3,200 global customers rely on the company’s SaaS-based platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes, and track progress on executing response plans. The company’s platform sent over 1.5 billion messages in 2016, and offers the ability to reach more than 200 countries and territories with secure delivery to over 100 different communication devices. The company’s critical communications and enterprise safety applications, which include Mass Notification, Incident Management, IT Alerting, Safety Connection™, Community Engagement™, Secure Messaging, Visual Command Center and Crisis Commander, are easy-to-use and deploy, secure, highly scalable and reliable. Everbridge serves 8 of the 10 largest U.S. cities, 8 of the 10 largest U.S.-based investment banks, all four of the largest global accounting firms, 24 of the 25 busiest North American airports and 6 of the 10 largest global automakers. Everbridge is based in Boston and Los Angeles with additional offices in San Francisco, Lansing, Beijing, London and Stockholm.

    Everbridge, Inc. raised $73.8 million in its upsized follow-on offering consisting of both primary and secondary shares at $19.85 per share. Needham acted as co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 451,825 shares at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Everbridge, Inc. for for general corporate purposes, including working capital and capital expenditures. Everbridge will not receive any proceeds from the sale of shares sold by the selling stockholders.

  • GigPeak, Inc. (NYSE MKT:GIG) is a leading innovator of semiconductor ICs and software solutions for high-speed connectivity and high-quality video compression over the network and the cloud. The focus of the company is to develop and deliver products that enable lower power consumption and faster data connectivity, more efficient use of network infrastructure, broader connectivity to the cloud, and reduce the total cost of ownership of existing network pipes from the core to the end user. GigPeak addresses both the speed of data transmission and the amount of bandwidth the data consumes within the network, and provides solutions that increase the efficiency of the Internet of Things, leveraging its strength in high-speed connectivity and high-quality video compression. The extended product portfolio provides more flexibility to support changing market requirements from ICs and MMICs through full software programmability and cost-efficient custom ASICs.

    Gigipeak Inc., a manufacturer of semiconductor ICs and software solutions for high-speed connectivity and high-quality video compression over the Network and the Cloud, completed its previously announced sale to Integrated Device Technology (NASDAQ: IDTI), a global leader in mixed signal semiconductor solutions for the advanced communications, computing and consumer industries, for $3.08 per share in cash or approximately $250 million. The acquisition of GigPeak provides IDT with a highly regarded optical interconnect product and technology business that is complementary to IDT's leadership position in real-time interconnect products. Needham & Company acted as a financial advisor to GigPeak, Inc.

  • Essen BioScience, Inc. develops and manufactures instruments, software, reagents and consumables which enable researchers to remotely image and quantitate a wide variety of cellular processes over time. The IncuCyte® System, is a real-time quantitative live-cell analysis platform that enables visualization and quantification of cell behavior over time by automatically gathering and analyzing images around the clock within a standard laboratory incubator. The system allows researchers to make time-lapsed fully kinetic measurements from living cells over days and weeks thus providing insight into active biological processes in real time. The company was founded in Ann Arbor, Michigan in 1996.

    Essen BioScience Inc., a pioneer and leader in the field of cell-based assays and instrumentation used for life sciences research, completed its previously announced sale to Sartorius Group AG (FWB: SRT), a leading partner to the biopharmaceutical industry and laboratories, for $320 million. Through this acquisition, Sartorius will significantly expand its portfolio for bioanalytics, a field the company has recently entered via the IntelliCyt acquisition in 2016. Needham & Company acted as a financial advisor to Essen BioScience Inc.

  • Cara Therapeutics (NASDAQ: CARA) is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system and have demonstrated, in Phase 2 trials, preliminary efficacy in patients with moderate-to-severe pain and pruritus without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

    Cara Therapeutics, Inc. raised $92.12 million in its follow-on offering at $18.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 667,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Cara Therapeutics, Inc. to fund the company's clinical and research development activities, including the completion of the Phase 3 program for I.V. CR845 in uremic pruritus, two Phase 3 trials of I.V. CR845 in acute pain and a Phase 2b trial of oral CR845 in osteoarthritis pain, as well as for working capital and general corporate purposes.

  • Analogix Semiconductor, Inc. designs and manufactures semiconductors for the digital multimedia market, from portable devices such as smartphones to high-end graphics cards and large, high-definition displays. Analogix is the market leader in providing end-to-end interface connectivity semiconductor solutions for DisplayPort, including high-speed signal conditioners and the SlimPort family of products, and an industry leader in mobile display controllers, such as low-power, high-speed timing controller solutions. The DisplayPort standard is an innovative, packetized digital interface for high-resolution video and audio that was developed by the Video Electronics Standards Association (VESA). SlimPort branded products are compliant with DisplayPort, Mobility DisplayPort (MyDP), and DisplayPort Alternate Mode over the USB Type-C connector.

    Analogix Semiconductor, Inc., a global leader in designing high-performance mixed-signal semiconductors that enable “HD Everywhere,” the go-anywhere, any-mobile-to-any-screen, high-definition experience, completed its previously announced sale to Beijing Shanhai Capital Management Co, Ltd. (Shanhai Capital), a pioneer buyout fund in healthcare and technology managing RMB and USD-denominated funds. Enhanced by the strong financial support of its new investors, Analogix will continue building and growing the company into a global leader in high-performance semiconductors. Needham & Company acted as a financial advisor to Analogix Semiconductor, Inc.

  • Cryoport, Inc. (NASDAQ: CYRX) is the life sciences industry's most trusted global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.

    Cryoport, Inc. raised $12.7 million in its follow-on offering at $2.00 per share. Needham acted as joint-bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 825,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Cryoport, Inc. for business growth, including as working capital and for other general corporate purposes.

  • EVRYTHNG is the Internet of Things Smart Products Platform connecting consumer products to the Web and managing real-time data to drive applications and analytics throughout the product lifecycle.

    Evrythng completed the pricing of its $24.8 million Series B funding round led by San Francisco-based Sway Ventures and also including Toronto-based Generation Ventures and London-based Bloc Ventures. Needham acted as sole placement agent for this transaction. The new investors join a strong base of existing backers including: Cisco Investments, Samsung, BHLP, Atomico, Dawn Capital and Advance Vixeid Partners. The funding will support EVRYTHNG’s growth through partnerships, the expansion of its team and continued development of its enterprise-focused IoT platform for managing intelligent software identities in the cloud and digital lifecycle applications for product manufacturers.

  • AXT, Inc. (NASDAQ: AXTI) designs, develops, manufactures and distributes high-performance compound and single element semiconductor substrates comprising indium phosphide (InP), gallium arsenide (GaAs) and germanium (Ge) through its manufacturing facilities in Beijing, China. In addition, AXT maintains its sales, administration and customer service functions at its headquarters in Fremont, California. The company’s substrate products can be used primarily in fiber optic communications, 3-D sensing, solar cell, lighting display applications and wireless communications. Its vertical gradient freeze (VGF) technique for manufacturing semiconductor substrates provides significant benefits over other methods and enabled AXT to become a leading manufacturer of such substrates. AXT has manufacturing facilities in China and, as part of its supply chain strategy, has partial ownership in ten companies in China producing raw materials.

    AXT Technology, Inc. raised $34.5 million in its follow-on offering at $6.50 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 692,307 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by AXT, Inc. for general corporate purposes, which may include the relocation of its gallium arsenide product line, working capital, capital expenditures and other corporate expenses.

  • Dermira, Inc. (NASDAQ: DERM) is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s product pipeline includes three Phase 3 product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate, in development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; and olumacostat glasaretil, in development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. raised $193.8 million in its upsized follow-on offering at $33.70 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 750,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dermira, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses. In addition, it will enable UCB to submit an sBLA to the FDA for potential approval of Cimzia; complete registration-enabling activities and submit an NDA to the FDA for potential approval related to glycopyrronium tosylate; enable the company to complete and generate topline results from their ongoing Phase 3 pivotal clinical trials for olumacostat glasaretil; commercialize their Cimzia and glycopyrronium tosylate product candidates assuming that the company receives the necessary regulatory approvals; complete registration-enabling activities and submit an NDA to the FDA for potential approval related to olumacostat glasaretil assuming the data from their Phase 3 clinical trials are positive; and commence potential lifecycle management activities related to their glycopyrronium tosylate and olumacostat glasaretil product candidates.

  • The Trade Desk, Inc. (NASDAQ:TTD) is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize more expressive data-driven digital advertising campaigns across ad formats, including display, video, audio, native and, social, on a multitude of devices, such as computers, mobile devices, and connected TV. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across the United States, Europe, and Asia.

    The Trade Desk, Inc. raised $258.5 million in its upsized follow-on offering at $35.50 per share of Class A common stock by certain selling stockholders . Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 949,798 shares of Class A common stock at the follow-on offering price to cover over-allotments. The Trade Desk will not receive any proceeds from the offering.

  • Athersys, Inc. (NASDAQ:ATHX) is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products.

    Athersys, Inc. raised $23.0 million in its follow-on offering at $1.01 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,970,300 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Athersys, Inc. for working capital and general corporate purposes, including funding towards its Phase 3 MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study-2 ("MASTERS-2") clinical study and its other ongoing clinical programs.

  • Applied Micro Circuits Corporation (NASDAQ: AMCC) is a global leader in computing andconnectivity solutions for next-generation cloud infrastructure and data centers. AppliedMicro delivers silicon solutions that dramatically lower total cost of ownership. Corporate headquarters are located in Sunnyvale, California. AppliedMicro became a wholly owned subsidiary of MACOM on 01/26/2017.

    Applied Micro Circuits Corporation (NASDAQ: AMCC), a global leader in computing and connectivity solutions, completed its previously announced sale to MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI), a leading supplier of high-performance RF, microwave, millimeterwave, and lightwave semiconductor products, for $764.9 million in the form of an exchange offer. Needham & Company acted as exclusive financial advisor to Applied Micro Circuits.

  • Kornit Digital (NASDAQ: KRNT) develops, manufactures and markets industrial digital printing technologies for the garment, apparel and textile industries. Kornit delivers complete solutions, including digital printing systems, inks, consumables, software and after-sales support. Leading the digital direct-to-garment printing market with its exclusive eco-friendly NeoPigment printing process, Kornit caters directly to the changing needs of the textile printing value chain. Kornit’s technology enables innovative business models based on web-to-print, on-demand and mass customization concepts. With its immense experience in the direct-to-garment market, Kornit also offers a revolutionary approach to the roll-to-roll textile printing industry: digitally printing with a single ink set onto multiple types of fabric with no additional finishing processes. Founded in 2003, Kornit Digital is a global company, headquartered in Israel with offices in the USA, Europe and Asia Pacific, and serves customers in more than 100 countries worldwide.

    Kornit Digital, Ltd. raised $142.3 million in its upsized follow-on offering public offering. Of the 7,500,000 ordinary shares, 2,000,000 of the shares are being offered by Kornit and 5,500,000 of the shares are being offered by shareholders of the company, substantially all by the company’s largest shareholder, Fortissimo Capital Fund II (Israel) LP at $16.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,125,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Kornit Digital for general corporate purposes. The Company will not receive any of the proceeds from the sale of shares being offered by the selling shareholders.

  • Exablox is the company reimagining storage. Exablox solves businesses’ runaway storage costs and information management nightmares by providing a cloud-managed, scale-out, object-based solution that is affordable and easy to use. OneBlox is an inclusive storage offering that combines an elegant hardware architecture and integrated, enterprise-grade software, including inline deduplication, continuous data protection and disaster recovery. Exablox’s innovative approach to storage has led to widespread customer traction across verticals including higher education, healthcare, insurance and the legal as well as Fortune 500 companies. As of January 19, 2017, Exablox Corporation operates as a subsidiary of StorageCraft Technology Corporation.

    Exablox Corporation, the award-winning company reimagining storage, completed its sale to StorageCraft, the intelligent recovery and backup company. StorageCraft Technology Corporation and Exablox Corporation joined forces to completely focus on helping businesses analyze, protect, and store their data. The new entity is the first company to bring together a new approach that recognizes the disappearing lines between primary and secondary storage as well as between data availability and data protection. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to Exablox Corporation.

  • Mediafly is an enterprise software company that has worked with some of the most respected global sales organizations. The Mediafly Evolved Selling Platform™ aligns with every sales training methodology and is a proven technology for helping field sales organizations deliver a dynamic, interactive, insightful buying experience that ties seamlessly back to CRM. For the third year in a row, Mediafly has been recognized by Inc. Magazine as one of the top 5000 fastest-growing private companies in the US. For more information, visit www.mediafly.com.

    Mediafly, a leading enterprise software company designed to help companies transform and evolve how they sell through the delivery of a perfect in-person selling experience, announced the closing of a $10 million growth capital investment from Boathouse Capital. This is the first outside institutional round for the company and will provide Mediafly with a financial partner to support industry leading product innovation to meet the growing demand for more effective sales tools from organizations around the world. As part of the transaction, Andy Jang, Vice President at Boathouse Capital, will be joining Mediafly's Board of Directors. Needham & Company acted as exclusive financial advisor to Mediafly on this transaction.

  • Ichor Holdings, Ltd. (NASDAQ: ICHR) is a leader in the design, engineering and manufacturing of critical fluid delivery subsystems for semiconductor capital equipment. Our primary offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. Our gas delivery subsystems deliver, monitor and control precise quantities of the specialized gases used in semiconductor manufacturing processes such as etch and deposition. Our chemical delivery subsystems precisely blend and dispense the reactive liquid chemistries used in semiconductor manufacturing processes such as electroplating and cleaning. We also manufacture certain components for internal use in fluid delivery systems and for direct sales to our customers. This vertically integrated portion of our business is primarily focused on metal and plastic parts that are used in gas and chemical systems, respectively.

    Ichor Holdings, Ltd. raised $60.84 million in its initial public offering at $9.00 per share. Needham acted as a passive bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 881,667 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Ichor Holdings to repay outstanding borrowings under their Credit Facilities and the remainder for general corporate purposes, including funding working capital, operating expenses and the selective pursuit of business development opportunities in their focus segment areas.

  • Impinj (NASDAQ:PI) is a leading provider of RAIN RFID solutions. The Impinj Platform connects billions of everyday items such as apparel, medical supplies, automobile parts, drivers’ licenses, food and luggage to applications such as inventory management, patient safety, asset tracking and item authentication, delivering real-time information to businesses about items they create, manage, transport and sell. The Impinj Platform wirelessly delivers information about these items’ unique identity, location and authenticity, or Item Intelligence™, to the digital world, which Impinj believes is the essence of the Internet of Things.

    Impinj, Inc. raised $109.2 million in its follow-on offering at $27.00 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 527,380 shares of common stock at the follow-on offering price to cover over-allotments. The number of shares sold in the offering included 1,527,380 shares sold by Impinj and 2,515,869 shares sold by certain selling stockholders. The net proceeds from the sale of the shares from the offering will be used by Impinj, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses. Impinj did not receive any proceeds from the sale of the shares by the selling stockholders.

  • TTM Technologies, Inc. (NASDAQ: TTMI) is a major global printed circuit board manufacturer, focusing on quick-turn and technologically advanced PCBs, backplane assemblies and electro-mechanical solutions. TTM stands for time-to-market, representing how TTM's time-critical, one-stop manufacturing services enable customers to shorten the time required to develop new products and bring them to market.

    TTM Technologies, Inc. raised $158.7 million in its follow-on offering of 12,000,000 shares of its common stock by its largest stockholder, Su Sih (BVI) Ltd. (the “Selling Stockholder”) at $11.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,800,000 shares of common stock at the follow-on offering price to cover over-allotments from the Selling Stockholder. The Selling Stockholder will receive all of the proceeds from the offering.

  • MSP Corporation is an instrumentation and equipment company creating products for scientific research and industrial applications. They are known worldwide for their expertise in micro- and nano-particles and their creative use in research and manufacturing. MSP is the world leader in cascade impactor technology with products serving the pharmaceutical and aerosol research markets, as well nano-particle generation and measurement technology serving the semiconductor device fabrication market. The company offers products through its distribution network worldwide. MSP Corporation was incorporated in 1985 and is based in Shoreview, Minnesota. As of November 9, 2016, MSP Corporation operates as a subsidiary of TSI Incorporated.

    MSP Group, an instrumentation and equipment company with an expertise in micro- and nano-particles and their creative use in research and manufacturing, completed its sale to TSI Incorporated, an industry leader in the design and production of precision instruments for measurements relating to aerosol science, air flow, health and safety, indoor air quality, fluid dynamics and biohazard detection. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to MSP Group.

  • The Chinese consortium of investors was comprised of Beijing-based IC design and solutions manufacturer Chipone Technology Co., Ltd ("Chipone") and its financial partner Beijing E-Town International Investment & Development Co., Ltd. ("E-Town Capital"). It focuses on technology, media and telecommunications, clean technology, semiconductors, and modern information service industry.

    A Chinese consortium comprised of Beijing-based IC design and solutions manufacturer Chipone Technology Co., Ltd ("Chipone") and its financial partner Beijing E-Town International Investment & Development Co., Ltd. ("E-Town Capital") announced that it has completed the acquisition of the Integrated Memory Logic Limited (iML) subsidiary of Exar Corporation (NYSE: EXAR), a leading supplier of analog mixed-signal semiconductor components and system solutions serving the industrial, high-end consumer and infrastructure markets, for a net purchase price of $136.0 million in cash. Needham & Company acted as exclusive financial advisor to the Chinese consortium.

  • Lavante, Inc. designs and develops a cloud-based supplier information management (SIM) and profit recovery system for Fortune 1000 companies. The company offers Lavante SIM, a transformational tool to manage and validate supplier profile automatically; Lavante Recovery, an on-demand recovery auditing solution; and Lavante Connect, a platform for connecting companies and suppliers. It serves hospitality, retail, entertainment, manufacturing, and medical industries. The company was formerly known as AuditSolutions Inc. and changed its name to Lavante, Inc. in April 2009. Lavante, Inc. was founded in 2001 and is based in San Jose, California. As of October 31, 2016, Lavante, Inc. operates as a subsidiary of PRGX USA, Inc.

    Lavante, Inc., a SaaS-based procure-to-pay (P2P) supplier information management (SIM) and recovery audit services firm, completed its sale to PRGX Global, Inc. (Nasdaq: PRGX), a global leader in Recovery Audit and Spend Analytics services. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to Lavante, Inc.

  • Theravance Biopharma, Inc. (NASDAQ: TBPH) is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma. For more information, please visit www.theravance.com.

    Theravance Biopharma, Inc. raised $115.1 million in its follow-on offering at $26.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 577,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Theravance Biopharma, Inc. for general corporate purposes, which may include, among other things, research activities, preclinical and clinical development of product candidates, manufacture of pre-clinical, clinical and commercial drug supplies, selling and marketing expenses, capital expenditures, working capital, general and administrative expenses and acquisitions of technology or drug candidates.

  • Theravance Biopharma, Inc. (NASDAQ: TBPH) is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma. For more information, please visit www.theravance.com.

    Theravance Biopharma, Inc. issued $230.0 million principal amount of Convertible Senior Notes due 2023. The Notes will be general unsecured obligations of the Company and will pay interest semi-annually on May 1 and November 1 of each year at a rate of 3.25% per year. The initial conversion rate of the Notes is 29.0276 ordinary shares per $1,000 principal amount of the Notes (which is equivalent to an initial conversion price of approximately $34.45 per share), and will be subject to adjustment upon the occurrence of certain events. The initial conversion price represents a conversion premium of approximately 32.5% over the sale price of ordinary shares sold in the Shares Offering. The Notes will mature on November 1, 2023, unless earlier repurchased or converted. The Notes will be convertible into ordinary shares of the Company at the then-applicable conversion rate until the close of business on the second business day immediately preceding the stated maturity date. The Notes will not be redeemable at the Company's option prior to maturity except in connection with certain changes in tax laws. Holders of the Notes will have the right to require the Company to repurchase all or any portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of certain fundamental change events. The underwriters fully exercised their option to purchase an additional $30 million in aggregate principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction. The Company intends to use the net proceeds of the offerings for general corporate purposes, which may include, among other things, research activities, preclinical and clinical development of product candidates, manufacture of pre-clinical, clinical and commercial drug supplies, selling and marketing expenses, capital expenditures, working capital, general and administrative expenses and acquisitions of technology or drug candidates.

  • Quantenna Communications, Inc. (NASDAQ: QNTA) is a provider of high-performance Wi-Fi solutions. Quantenna’s solutions combine semiconductor architecture with system-level software and cloud analytics with the goal of delivering the highest speed, broadest coverage, highest capacity, and most reliable performance. Quantenna’s solutions primarily serve the non-mobile device market.

    Quantenna Communications, Inc. raised $108.4 million in its initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 75,466 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Quantenna Communications for general corporate purposes, including working capital, operating expenses and capital expenditures. The company may also use a portion of the net proceeds to acquire complementary businesses, products, services or technologies.

  • Collegium Pharmaceutical, Inc. (Nasdaq:COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceutical, Inc. raised $92.0 million in its follow-on offering at $16.00 per share. Needham acted as a co-lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 750,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Collegium Pharmaceutical, Inc. for the continued commercialization of Xtampza; funding research and development efforts of its other product candidates; and working capital and general corporate purposes, which may include the acquisition or licensing of product candidates, technologies, compounds, other assets or complementary businesses.

  • Everspin Technologies (NASDAQ: MRAM) is the leading provider of MRAM solutions. Everspin’s MRAM solutions offer the persistence of non-volatile memory with the speed and endurance of random access memory (RAM), and enable the protection of mission critical data particularly in the event of power interruption or failure. Everspin’s MRAM solutions allow its customers in the industrial, automotive and transportation, and enterprise storage markets to design high performance, power efficient and reliable systems without the need for bulky batteries or capacitors. Everspin is the only provider of commercially available MRAM solutions and over the past eight years has shipped over 60 million MRAM units. For more information, visit www.everspin.com.

    Everspin Technologies raised $40.0 million in its initial public offering at $8.00 per share. Needham acted as a joint-bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Everspin Technologies for are to obtain additional capital, to create a public market for our common stock and to facilitate future access to the public equity markets. The company expects to use the net proceeds received from this offering for working capital and other general corporate purposes, including an estimated payment of $8.5 million due to GLOBALFOUNDRIES in December 2016, research and development activities, sales and marketing activities and capital expenditures, to enhance existing and develop new products, expand our manufacturing capabilities and to fund growth.

  • Acacia Communications (NASDAQ: ACIA) develops, manufactures and sells high-speed coherent optical interconnect products that are designed to transform communications networks through improvements in performance, capacity and cost. By converting optical interconnect technology to a silicon-based technology, a process Acacia refers to as the “siliconization of optical interconnect,” Acacia is able to offer products that meet the needs of cloud and service provider customers in a simple, open, high-performance form factor that can be easily integrated in a cost-effective manner with existing network equipment.

    Acacia Communications, Inc. raised $450.0 million in its follow-on offering at $100.00 per share. The offering consists of 1,210,302 shares from Acacia Communications and 3,289,698 shares from certain existing stockholders. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Acacia Communications, Inc. for working capital and general corporate purposes. Acacia Communications will not receive any of the proceeds from any sale of shares by the selling stockholders.

  • Nutanix, Inc. (NASDAQ: NTNX) makes infrastructure invisible, elevating IT to focus on the applications and services that power their business. The Nutanix enterprise cloud platform leverages web-scale engineering and consumer-grade design to natively converge compute, virtualization and storage into a resilient, software-defined solution with rich machine intelligence. The result is predictable performance, cloud-like infrastructure consumption, robust security, and seamless application mobility for a broad range of enterprise applications.

    Nutanix, Inc. raised $273.61 million in its upsized initial public offering of Class A common stock at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,230,500 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Nutanix, Inc. for general corporate purposes, including working capital, sales and marketing activities, research and development and general and administrative matters.

  • Sarepta Therapeutics (NASDAQ: SRPT) is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including EXONDYS 51, designed to skip exon 51 and approved under the accelerated approval pathway.

    Sarepta Therapeutics, Inc. raised $345.0 million in its follow-on offering at $59.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 753,138 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Sarepta Therapeutics, Inc. principally for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities including the potential licensing or acquisition of complementary products and technologies and other general corporate purposes.

  • Oclaro, Inc. (NASDAQ: OCLR) is a leader in optical components, modules and subsystems for the core optical, enterprise and data center markets. Leveraging more than three decades of laser technology innovation, photonics integration, and subsystem design, Oclaro's solutions are at the heart of the fast optical networks and high-speed interconnects driving the next wave of streaming video, cloud computing, voice over IP and other bandwidth-intensive and high-speed applications.

    Oclaro, Inc. raised $144.04 million in its upsized follow-on offering at $8.35 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,250,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Oclaro, Inc. for general corporate purposes, including working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses.

  • The Trade Desk, Inc. (NASDAQ: TTD) is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize more expressive data-driven digital advertising campaigns across ad formats, including display, video, audio, native and, social, on a multitude of devices, such as computers, mobile devices, and connected TV. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across the United States, Europe, and Asia.

    The Trade Desk, Inc. raised $96.6 million in its initial public offering of its Class A common stock at $18.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 700,000 shares of common stock at the initial public offering price to cover over-allotments. The Trade Desk will not receive any proceeds from the sale of shares by the selling stockholders.

  • Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP) is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. With a successful Phase 2 clinical trial completed in 2015, Aquinox initiated a Phase 3 trial in 2016 (LEADERSHIP 301) with AQX-1125 for treatment of IC/BPS. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.

    Aquinox Pharmaceuticals, Inc. raised $75.4 million in its follow-on offering at $12.25 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 802,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Aquinox Pharmaceuticals, Inc. to fund additional clinical development of AQX-1125 and to fund pre-commercial and market assessment activities, research and development costs to advance its pipeline of preclinical product candidates and for working capital and other general corporate purposes.

  • DFMSim provides advanced enabling software solutions to the global semiconductor industry. The company's technology simulates key IC design and processing steps to quickly find and avoid systemic defects that threaten yields and increase manufacturing costs. DFMSim's solutions are versatile, modular, easy to use and can be rapidly configured for various manufacturing processes and tools. Headquartered in Silicon Valley, the company maintains R&D, sales and support offices in multiple global locations.

    DFMSim Inc., a leader in chip simulation technology, completed its sale to Applied Materials (NASDAQ: AMAT), the global leader in providing innovative equipment, services and software to enable the manufacture of advanced semiconductor, flat panel display and solar photovoltaic products. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to DFMSim Inc.

  • Inphi Corporation (NYSE: IPHI) is a leader in high-speed data movement. We move big data - fast, throughout the globe, between data centers, and inside data centers. Inphi's expertise in signal integrity results in reliable data delivery, at high speeds, over a variety of distances. As data volumes ramp exponentially due to video streaming, social media, cloud-based services, and wireless infrastructure, the need for speed has never been greater. That's where we come in. Customers rely on Inphi's solutions to develop and build out the Service Provider and Cloud infrastructures, and data centers of tomorrow.

    Inphi Corporation issued $287.5 million principal amount of Convertible Senior Notes due 2021 in an upsized transaction to qualified institutional buyers pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). Inphi will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. In addition, holders may require Inphi to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the repurchase date. The underwriters fully exercised their option to purchase an additional $37.5 million in aggregate principal amount of notes to cover over-allotments. Needham & Company acted as a co-manager for this transaction. Inphi intends to use a portion of the net proceeds from the offering of the notes to pay the cost of certain capped call transactions. Inphi intends to use the remainder of the net proceeds from the offering of the notes for general corporate purposes, including financing potential acquisitions and other strategic transactions.

  • EMC Corporation (NYSE:EMC) is a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service. Fundamental to this transformation is cloud computing. Through innovative products and services, EMC accelerates the journey to cloud computing, helping IT departments to store, manage, protect and analyze their most valuable asset – information – in a more agile, trusted and cost-efficient way.

    EMC Corporation (NYSE: EMC), a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service, completed its historic previously announced sale to Dell Technologies, creating a unique family of businesses that provides the essential infrastructure for organizations to build their digital future, transform IT and protect their most important asset, information. This combination creates a $74 billion market leader with an expansive technology portfolio that solves complex problems for customers in the industry’s fast-growing areas of hybrid cloud, software-defined data center, converged infrastructure, platform-as-a-service, data analytics, mobility and cybersecurity. Under the terms of the transaction, EMC shareholders received $24.05 per share in cash in addition to tracking stock linked to a portion of EMC’s economic interest in the VMware business. Based on the estimated number of EMC shares outstanding at close, EMC shareholders received 0.11146 shares of new tracking stock (NYSE: DVMT) for each EMC share. It is the largest technology transaction on record and Dell Technologies now becomes the world’s largest privately-controlled technology company. Needham & Company acted as a financial advisor to EMC on this transaction.

  • Galvanize is a dynamic tech learning community that offers education, workspace and networking for students, startups and large companies. Galvanize teaches web development, data science and data engineering to students, offers support and workspace to over 700 member companies and provides over 200 networking events across nine urban campuses throughout the nation. Galvanize campuses bring together entrepreneurs, students, investors, mentors, and great people and companies to develop the skills, mindset and networks necessary to thrive in a technology driven world.

    Galvanize, Inc., a market leader delivering technology education programs and community workspaces, announced a $45 million Series B investment led by ABS Capital Partners, a leading late-stage growth company investor. Colorado Impact Fund, Haystack Partners, Greg Maffei, Aspen Grove Capital and existing investor University Ventures also participated. Needham acted as financial advisor and sole agent to Galvanize on this transaction. The funding will be used to provide more students access to Galvanize’s modern web development and data science programs and directly address employer’s needs to re-skill existing employees. As a result of the financing, Paul Mariani, a general partner with ABS Capital, will join the Galvanize Board of Directors.

  • ACADIA Pharmaceuticals, Inc (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

    ACADIA Pharmaceuticals, Inc. raised $230.0 million in its follow-on offering at $33.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 909,090 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals, Inc. for to fund commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin, and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and sales, general and administrative expenses. The company may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.

  • Digimarc Corporation (NASDAQ: DMRC), based in Beaverton, Oregon, is the inventor of the Digimarc Discover® platform featuring the imperceptible Digimarc Barcode for automatically identifying and interacting with virtually any media. Digimarc owns an extensive intellectual property portfolio, with patents in digital watermarking, content identification and management, media object discovery, and intuitive computing more generally.

    Digimarc, Inc. raised $42.5 million in its upsized follow-on offering at $30.00 per share. Needham acted as the joint bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 185,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Digimarc, Inc. for for general working capital purposes as well as to accelerate the Company’s growth initiatives. These growth initiatives include increasing sales, marketing and operations resources for global expansion; supporting a growing supplier network, and feasibility and pilot projects with prospective customers; continuing development of tools and processes to support efficient, effective and timely implementation of its technology; and further research and intellectual property development.

  • UnboundID provides the industry’s leading software platform for customer identity and access management. Enterprise customers select the UnboundID Platform to modernize traditional Identity and Access Management systems, and enable new customer-facing digital business initiatives that provide real-time personalization and delivery of a consistent customer experience across channels and devices. Some of the world’s largest and most demanding companies in financial services, retail, hospitality, telecommunications and healthcare rely on UnboundID to manage and protect their identity and preference data across application portfolios and systems of engagement. UnboundID customers consistently report a total cost of ownership savings between 25 to 90 percent relative to legacy directory servers, and the company enjoys a 100% customer renewal rate.

    UnboundID, a market leading provider of customer identity and access management software, to help enterprises improve customer engagement, completed its sale to Ping Identity, the leader in Identity Defined Security. Terms of the transaction were not disclosed. The deal puts Ping Identity, which is owned by Vista Equity Partners, firmly in at the intersection of identity and customer engagement and management. The combined company provides Identity and Access Management solutions for the world’s leading companies, including over half of the Fortune 100, and manages over 3 billion identities. Needham & Company acted as the exclusive financial advisor to UnboundID.

  • Ellie Mae, Inc. (NYSE:ELLI) is a leading provider of innovative on-demand software solutions and services for the residential mortgage industry. Mortgage lenders of all sizes use Ellie Mae’s Encompass® all-in-one mortgage management solution, Mavent Compliance Service, and AllRegs research, reference and education resources to improve compliance, loan quality and efficiency across the entire mortgage lifecycle.

    Ellie Mae, Inc. raised $284.63 million in its follow-on offering at $90.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 412,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Ellie Mae, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Argos Therapeutics (NASDAQ: ARGS) is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients.

    Argos Therapeutics, Inc. raised $50.0 million in its follow-on offering at $5.50 per share of common stock and accompanying warrants . Needham acted as the lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Argos Therapeutics, Inc. to fund their pivotal Phase 3 ADAPT trial of AGS-003, the ongoing and planned investigator-initiated Phase 2 clinical trials of AGS-003, their share of the expected costs of the leasing, build-out and equipping of a commercial manufacturing facility and activities in preparation for the submission of a BLA to the FDA for AGS-003, and for working capital and other general corporate purposes.

  • Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.

    Nicox S.A. completed the pricing of an offering a reserved capital increase of ordinary shares of the Company to a specific category of investors. The gross proceeds of the financing are approximately €18 million, for a total of 2,064,000 million new shares. Needham acted as lead placement agent for this transaction. The net proceeds from the sale of the Units will be used by Nicox S.A. for clinical development of pipeline candidates (NCX 4251 in blepharitis and NCX 470 in glaucoma), working capital and general corporate purposes.

  • Impinj (NASDAQ: PI) is a leading provider of RAIN RFID solutions. The Impinj Platform connects billions of everyday items such as apparel, medical supplies, automobile parts, drivers’ licenses, food and luggage to applications such as inventory management, patient safety, asset tracking and item authentication, delivering real-time information to businesses about items they create, manage, transport and sell. The Impinj Platform wirelessly delivers information about these items’ unique identity, location and authenticity, or Item Intelligence™, to the digital world, which Impinj believes is the essence of the Internet of Things.

    Impinj, Inc. raised $77.3 million in its upsized initial public offering at $14.00 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 720,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Impinj, Inc. to repay $5.0 million of indebtedness under the mezzanine credit facility and the remainder will be used for working capital and other general corporate purposes.

  • FormFactor, Inc. (NASDAQ: FORM) helps semiconductor manufacturers test the integrated circuits (ICs) that power consumer mobile devices, as well as computing, automotive and other applications. The company is one of the world’s leading providers of essential wafer test technologies and expertise, with an extensive portfolio of high-performance probe cards for DRAM, Flash and SoC devices. Customers use FormFactor’s products and services to lower overall production costs, improve their yields and enable complex next-generation ICs. Headquartered in Livermore, California, the company services its customers from a network of facilities in Europe, Asia and North America.

    FormFactor, Inc. (Nasdaq:FORM) announced that it has completed the acquisition of Cascade Microtech, Inc. (NASDAQ: CSCD),a worldwide leader in precision contact, electrical measurement and test of integrated circuits (ICs), optical devices and other small structures, for a net purchase price of $352 million in cash and stock. Needham & Company acted as the exclusive financial advisor and provided a fairness opinion to the Board of Directors of FormFactor, Inc. as part of its services.

  • Esperion Therapeutics, Inc. (NASDAQ: ESPR) is the Lipid Management Company passionately committed to developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated LDL-C. Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced lipid management team at Esperion is committed to developing new LDL-C lowering therapies that will make a substantial impact on reducing global cardiovascular disease; the leading cause of death around the world. Bempedoic acid and the company's lead product candidate, the bempedoic acid / ezetimibe combination, are targeted therapies that have been shown to significantly reduce elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. For more information, please visit www.esperion.com

    Esperion Therapeutics, Inc. raised $151.9 million in its follow-on offering at $49.00 per share. Needham acted as co-manager on the transaction. Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to continue to fund the CLEAR Outcomes cardiovascular outcomes trial for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia, or who are at high risk for cardiovascular disease, and who are only able to tolerate less than the lowest approved daily starting doses of a statin and can be considered statin intolerant; support the New Drug Application and Marketing Authorization Application submission activities and its operations through regulatory approvals for LDL-C lowering indications for the bempedoic acid / ezetimibe combination pill and bempedoic acid; support pre-commercial launch activities for the bempedoic acid / ezetimibe combination pill and bempedoic acid; initiate development activities for a reformulated tablet of bempedoic acid for nonalcoholic steatohepatitis (NASH) indications; and for working capital and general corporate and administrative expenses.

  • Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL; Nasdaq Global Select Market: ZEAL) is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand is based in Copenhagen (Glostrup), Denmark.

    Zealand Pharma A/S raised $89.1 million in its initial public offering of American Depository Shares at $17.87 per share. Needham acted as a co-lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 656,250 ADSs at the initial public offering price to cover over-allotments.

  • Perfect Commerce provides world-class sourcing and procurement solutions to the enterprise and public market sectors. Automating spend management initiatives since 1994, Perfect offers a true end-to-end platform that enables businesses to reduce costs while increasing operational efficiency. The Perfect Suite of software and services solves complex industry challenges, throughout the spend lifecycle.

    Perfect Commerce, a leading SaaS-based provider of end-to-end procurement solutions, today announced that it has completed its reverse takeover by PROACTIS Holdings (LON: PHD), a global Spend Control and eProcurement solution provider, will pay $127.5 million at completion in cash and through the issue of a $5.0 million convertible acquisition loan note, and up to a further $5.0 million in cash upon the occurrence of specified events during the period to July 31, 2018. Needham & Company acted as exclusive financial advisor to Perfect Commerce LLC.

  • Ichor Holdings, Ltd. (NASDAQ: ICHR) is a leader in the design, engineering and manufacturing of critical fluid delivery subsystems for semiconductor capital equipment. Our primary offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. Our gas delivery subsystems deliver, monitor and control precise quantities of the specialized gases used in semiconductor manufacturing processes such as etch and deposition. Our chemical delivery subsystems precisely blend and dispense the reactive liquid chemistries used in semiconductor manufacturing processes such as electroplating and cleaning. We also manufacture certain components for internal use in fluid delivery systems and for direct sales to our customers. This vertically integrated portion of our business is primarily focused on metal and plastic parts that are used in gas and chemical systems, respectively.

    Ichor Holdings, Ltd. raised $122.2 million in its follow-on offering at $19.32 per share by selling shareholders. Needham acted as passive bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 825,000 shares of common stock at the follow-on offering price to cover over-allotments. Ichor Holdings, Ltd. will not receive any proceeds from the offering.

  • ViXS Systems (TSX: VXS) is a pioneer and market leader in designing revolutionary media processing semiconductor solutions for video over IP streaming solutions, with more than 470 patents issued and pending worldwide, numerous industry awards for innovation, and over 33 million media processors shipped to date. ViXS is driving the transition to Ultra HD 4K across the entire content value chain by providing professional and consumer grade chipsets that support the new High Efficiency Video Coding (HEVC) standard up to Main 12 Profile, reducing bandwidth consumption by 50% while providing the depth of color and image clarity needed to take advantage of higher-resolution content. ViXS’ XCodePro 300 family is ideal for Ultra HD 4K infrastructure equipment, and the XCode 6000 family of system-on-chip (SoC) products achieve unprecedented levels of integration that enable manufacturers to create cost-effective consumer entertainment devices. ViXS is headquartered in Toronto, Canada with offices in Europe, Asia and North America. VIXS™, the ViXS® logo, XCode®, XCodePro™ and Xtensiv™ are trademarks and/or registered trademarks of ViXS. Other trademarks are the property of their respective owners.

    ViXS Systems (TSX: VXS), a pioneer and leader in media processing solutions, today announced that it has sold its legacy MoCA (Multimedia over Coaxial Alliance) business to Pixelworks (NASDAQ: PXLW), a provider of visual processing solutions, in an in an all-stock transaction valued at $20.2 million. Needham & Company acted as exclusive financial advisor to ViXS Systems.

  • Regulus Therapeutics Inc. is a biopharmaceutical company developing innovative medicines targeting microRNAs. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Regulus maintains its corporate headquarters in La Jolla, CA.

    Regulus Therapeutics, Inc. raised $46.0 million in its follow-on offering at $0.91 per share. Needham acted as co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 6,600,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering together with other available funds, will be used by Alder Regulus Therapeutics Inc. to fund clinical development of its clinical candidates, RG-012 and RGLS4326, development of its earlier microRNA development candidates and programs, for the identification and validation of additional microRNA targets, and for capital expenditures, working capital and general corporate purposes.

  • Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), is a clinical-stage biopharmaceutical company committed to transforming the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions. Leveraging its pioneering monoclonal antibody technologies, Alder discovers and develops novel therapeutic antibodies designed to deliver highly differentiated, best-in-class clinical profiles. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody administered quarterly via infusion that allows for 100% of the dose available to selectively and potently inhibit the calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.

    Alder Biopharmaceuticals, Inc. raised $172.5 million in its follow-on offering at $10.00 per share. Needham acted as co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,250,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering together with other available funds, will be used by Alder Biopharmaceuticals, Inc. to fund the continued development of eptinezumab, including completion of the ongoing infusion pivotal trial program, the planned submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), establishment of the commercial drug supply chain and other commercialization activities, and for working capital and general corporate purposes.

  • Tintri, Inc. (NASDAQ: TNTR) offers an enterprise cloud infrastructure built on a public cloud-like web services architecture and RESTful APIs. Organizations use Tintri all-flash storage with scale-out and automation as a foundation for their own clouds—to build agile development environments for cloud native applications and to run mission critical enterprise applications. Tintri enables users to guarantee the performance of their applications, automate common IT tasks to reduce operating expenses, troubleshoot across their infrastructure, and predict an organization’s needs to scale—the underpinnings of a modern data center. That’s why leading cloud service providers and enterprises, including Comcast, Chevron, NASA, Toyota, United Healthcare and 21 of the Fortune 100 companies, trust Tintri with enterprise cloud.

    Tintri, Inc. raised $67.0 million in its initial public offering at $7.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 1,000,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Tintri, Inc. for general corporate purposes including working capital, product development and operating expenses. Furthermore, the Company may use a portion of the net proceeds from this offering to repay outstanding indebtedness, including indebtedness under our loan and security agreements with SVB and TriplePoint.

  • Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia's lead product candidate, vadadustat, is an oral, investigational therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing.

    Akebia Therapeutics, Inc. raised $66.7 million in its follow-on offering at $14.50 per share. Needham acted as senior co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 600,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. for for the continued clinical development of vadadustat, including adding manufacturing capabilities; for clinical development of AKB-5169; for discovery, research and preclinical studies of our other product candidates; and the remainder for working capital, business development and other general corporate purposes.

  • Blue Apron Holdings, Inc. (NASDAQ: APRN) has a mission to make incredible home cooking accessible to everyone. Launched in 2012, Blue Apron is reimagining the way that food is produced, distributed, and consumed, and as a result, building a better food system that benefits consumers, food producers, and the planet. The company has developed an integrated ecosystem that enables the company to work in a direct, coordinated manner with farmers and artisans to deliver high-quality products to customers nationwide at compelling values. Blue Apron’s current products include Blue Apron Meals, Blue Apron Wine, the Blue Apron Market, and BN Ranch, a premium supplier of grass-fed beef and pasture-raised poultry.

    Blue Apron Holdings, Inc. raised $300.0 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by Blue Apron Holdings, Inc. for working capital, capital expenditures and general corporate purposes.

  • Nor-Cal Products Inc. ("Nor-Cal"), is a leading manufacturer of premium-quality vacuum components, chambers and valves for international customers in the fields of semiconductors, coating and displays as well as for leading universities and research facilitiesFounded in 1962 in Yreka, California, USA, Nor-Cal operates plants at its Yreka headquarters and in Ho-Chi-Minh-City, Vietnam, which will further improve the group's global production footprint. In recent years, the company has benefited greatly from its persistent focus on customers in the semiconductor industry and this segment's comparatively high growth. Nor-Cal has identified the medical engineering sector in North America as another very interesting future growth market.

    Nor-Cal Products Inc. ("Nor-Cal"), a leading manufacturer of premium-quality vacuum components, chambers and valves for international customers in the fields of semiconductors, coating and displays as well as for leading universities and research facilities, completed its previously announced sale to Pfeiffer Vacuum Technology AG (ETR: PFV), for $68 million in cash. Needham & Company acted as a financial advisor to Nor-Cal.

  • WageWorks, Inc. (NYSE: WAGE) is a leader in administering Consumer-Directed Benefits (CDBs). WageWorks is solely dedicated to administering CDBs, including pre-tax spending accounts, such as Health Savings Accounts (HSAs), health and dependent care Flexible Spending Accounts (FSAs), Health Reimbursement Arrangements (HRAs), as well as Commuter Benefit Services, including transit and parking programs, wellness programs, COBRA, and other employee benefits. WageWorks makes it easier to understand and take advantage of Consumer-Directed Benefits for more than 100,000 employers and approximately 6.5 million people. WageWorks is headquartered in San Mateo, California, with offices in major locations throughout the United States. For more information, visit www.wageworks.com.

    WageWorks, Inc. raised $173.1 million in its follow-on offering of 1,954,852 Primary and 545,148 Secondary Shares at $69.25 per share. Needham acted as a co-manager on the transaction. The net proceeds from the primary portion of the offering will be used by WageWorks, Inc. for general corporate purposes, including strategic acquisitions, channel partner arrangements, capital expenditures and operating costs. WageWorks, Inc. will not receive any proceeds from the sale of shares by the selling stockholders.

  • Adesto Technologies (NASDAQ:IOTS) is a leading provider of application-specific, ultra-low power, smart non-volatile memory products. The company has designed and built a portfolio of innovative products with intelligent features to conserve energy and enhance performance, including Fusion Serial Flash, DataFlash®, EcoXiP™ and products based on its trademark resistive RAM technology called Conductive Bridging RAM (CBRAM®). CBRAM® is a breakthrough technology platform that enables 100 times less energy consumption than today’s flash memory technologies as well as delivering enhanced performance.

    Adesto Technologies Corporation raised $20.0 million in its follow-on offering at $4.00 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 625,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Adesto Technologies Corporation for general corporate purposes.

  • Crisp Mobile has over 15 years’ experience in delivering marketer content via mobile devices. Crisp’s exclusive focus on the Retail and CPG markets means that only Crisp has both the deep vertical knowledge and the proven ability to activate shoppers on the device they use most often: their mobile phone. Crisp provides the industry’s first end-to-end mobile customer activation platform to deliver radically improved mobile experiences for shoppers and marketers alike. These unrivaled experiences, along with a proven ability to deliver results, have made Crisp a trusted partner to many of today’s largest retail and CPG brands.

    Crisp Mobile, a mobile marketing and advertising company primarily serving CPG and retail customers, completed its previously announced sale to Quotient Technology Inc. (NYSE:QUOT), a leading digital promotions, media and analytics company that connects brands, retailers and shoppers, for approximately $57.5 million. While Crisp will continue to operate as its own brand, Quotient will take advantage of the natural synergies as Quotient expands their efforts in shopper marketing. Needham & Company acted as exclusive financial advisor to Crisp Mobile.

  • Upland Software, Inc. (NASDAQ: UPLD) is a leading provider of cloud-based Enterprise Work Management software. Its family of applications enables users to manage their projects, professional workforce, and IT investments; automate document-intensive business processes; and effectively engage with their customers, prospects, and community via the web and mobile technologies. With more than 2,500 customers and over 250,000 users around the world, Upland solutions help customers run their operations smoothly, adapt to change quickly, and achieve better results every day.

    Upland Software, Inc. raised $46.0 million in its upsized follow-on offering at $21.50 per share. Needham acted as joint bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 279,069 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Upland Software, Inc. for general corporate purposes. General corporate purposes may include additions to working capital, financing of capital expenditures, repayment or redemption of existing indebtedness, repurchases of stock, and future acquisitions and strategic investment opportunities.

  • LendingTree, Inc. (NASDAQ: TREE) operates the nation's leading online loan marketplace and provides consumers with an array of online tools and information to help them find the best loans for their needs. LendingTree's online marketplace connects consumers with multiple lenders that compete for their business, empowering consumers as they comparison-shop across a full suite of loans and credit-based offerings. Since its inception, LendingTree has facilitated more than 65 million loan requests. LendingTree provides access to its network of over 500 lenders offering home loans, home equity loans/lines of credit, reverse mortgages, personal loans, auto loans, small business loans, credit cards, student loans and more. LendingTree, Inc. is headquartered in Charlotte, NC and maintains operations solely in the United States.

    LendingTree, Inc. issued $300.0 million convertible senior notes due 2022 (the "Notes") in an upsized private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The underwriters fully exercised their option to purchase an additional $35.00 million in aggregate principal amount of the Notes to cover overallotments. Needham & Company acted as a co-manager for this transaction. LendingTree, Inc. intends to use the net proceeds from the Notes offering for general corporate purposes including, but not limited to, working capital and potential acquisitions.

  • Corium International, Inc. (NASDAQ: CORI) is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company’s broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer’s disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Endo Pharmaceuticals and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company’s late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being developed with other partners.

    Corium International, Inc. raised $40.3 million in its upsized follow-on offering at $6.25 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 840,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Corium International, Inc. to offering for product development and general corporate purposes, which may include funding research and development, increasing its working capital, reducing indebtedness, acquisitions or investments in businesses, products or technologies that are complementary to its own and capital expenditures.

  • Albireo Pharma, Inc. (NASDAQ: ALBO) is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 3 product candidates and one Phase 2 product candidate. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden.

    Albireo Pharma, Inc. raised $51.9 million in its upsized follow-on offering at $20.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 330,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Albireo Pharma, Inc. to complete the Phase 3 clinical program of A4250 to treat patients with PFIC; to initiate a clinical trial of A4250 in one or more additional pediatric cholestatic liver diseases; to initiate a Phase 2 clinical trial of A3384 to treat BAM; to advance our preclinical program in NASH and, if the company select a product candidate from their NASH program for clinical development, to complete the preclinical development activities necessary to initiate a Phase 1 clinical trial of the product candidate; and for general corporate purposes.

  • SMART Global Holdings (NASDAQ: SGH), the parent company of SMART Modular Technologies, Inc., is a global leader in specialty memory solutions, serving the electronics industry for over 25 years and holds a leading, international, market position, as measured by revenue, in specialty memory.

    SMART Global Holdings, Inc. raised $67.05 million in its initial public offering at $11.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 795,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by SMART Global Holdings, Inc. to repay a portion of their outstanding term loans under the Senior Secured Credit Agreement. In addition, the company intends to use $4.7 million of the net proceeds to make a payment to affiliates of Silver Lake for unpaid management fees in respect of past periods under the Amended and Restated Transaction and Management Fee Agreement, which they intend to terminate upon the completion of this offering. The remaining net proceeds shall be used for general corporate purposes.

  • The Trade Desk, Inc. (NASDAQ:TTD) is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize more expressive data-driven digital advertising campaigns across ad formats, including display, video, audio, native and, social, on a multitude of devices, such as computers, mobile devices, and connected TV. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across the United States, Europe, and Asia.

    The Trade Desk, Inc. raised $252.0 million in its upsized follow-on offering at $52.0 per share of Class A common stock by certain selling stockholders . Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 530,148 shares of Class A common stock at the follow-on offering price to cover over-allotments. The Trade Desk will not receive any proceeds from the offering.

  • G1 Therapeutics, Inc. (NASDAQ: GTHX) is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is based in Research Triangle Park, NC.

    G1 Therapeutics, Inc. raised $116.72 million in its upsized initial public offering at $15.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 781,564 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by G1 Therapeutics, Inc. to advance the product development of trilaciclib, G1T38 & G1T48 and general corporate purposes including working capital and operating expenses.

  • Concurrent Computer Corporation (NASDAQ:CCUR) is a global software and solutions company that develops advanced applications focused on storing, protecting, transforming, and delivering high value media assets. We serve industries and customers that demand uncompromising performance, reliability and flexibility to gain a competitive edge, drive meaningful growth and confidently deliver best-in-class solutions that enrich the lives of millions of people around the world every day. Offices are located in North America, Europe and Asia.

    Concurrent Computer Corporation (NASDAQ: CCUR), a global software and solutions company that develops advanced applications focused on storing, protecting, transforming, and delivering high value media assets, completed its previously announced sale of its Real-Time business segment to Battery Ventures for $35 million in cash. The Real-Time business segment will operate as an independent, privately-held company doing business as Concurrent Real-Time, Inc. Needham & Company acted as financial advisor to Concurrent Computer Corporation.

  • Dermira, Inc. (NASDAQ: DERM) is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s product pipeline includes three Phase 3 product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate, in development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; and olumacostat glasaretil, in development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. issued $287.5 million aggregate principal amount of 3.00% Convertible Senior Notes due 2022 (the “notes”) in a private offering to qualified institutional buyers pursuant to the Securities Act of 1933, as amended (the “Securities Act”). The underwriters fully exercised their option to purchase an additional $37.5 million in aggregate principal amount of the Notes to cover overallotments. Needham & Company acted as a co-manager for this transaction. Dermira intends to use the net proceeds that it receives from the note offering for working capital, capital expenditures and other general corporate purposes. Dermira may also use a portion of the net proceeds from this offering to expand its business by in-licensing or acquiring, as the case may be, product candidates, technologies, compounds, other assets, commercial products or complementary businesses.

  • Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has licensed intellectual property from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven is a company organized under the laws of the British Virgin Islands and its United States operations are based in New Haven, Connecticut.

    Biohaven Pharmaceuticals Holding Company Ltd. raised $193.5 million in its initial public offering at $17.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,485,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Biohaven Pharmaceuticals to initiate and complete two Phase 3 clinical trials of rimegepant for the acute treatment of migraine; fund continued research and development of BHV-3500 for the prevention of chronic and episodic migraine; complete ongoing Phase 2/3 trial of trigriluzole for the treatment of SCA; fund continued research and development of BHV-5000 for the treatment of breathing irregularities associated with Rett syndrome, including completion of planned Phase 1 clinical trial for this indication; repay aggregate indebtedness under credit agreement with Wells Fargo and notes payable to related parties; satisfy remaining obligation to purchase shares of capital stock of Kleo Pharmaceuticals; and fund other research and development activities, including the development of BHV-0223 for the treatment of ALS, as well as for working capital and other general corporate purposes, including the satisfaction of any milestone payment obligations under license agreements.

  • Ichor Holdings, Ltd. (NASDAQ: ICHR) is a leader in the design, engineering and manufacturing of critical fluid delivery subsystems for semiconductor capital equipment. Our primary offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. Our gas delivery subsystems deliver, monitor and control precise quantities of the specialized gases used in semiconductor manufacturing processes such as etch and deposition. Our chemical delivery subsystems precisely blend and dispense the reactive liquid chemistries used in semiconductor manufacturing processes such as electroplating and cleaning. We also manufacture certain components for internal use in fluid delivery systems and for direct sales to our customers. This vertically integrated portion of our business is primarily focused on metal and plastic parts that are used in gas and chemical systems, respectively.

    Ichor Holdings, Ltd. raised $115.2 million in its upsized follow-on offering at $19.50 per share by selling shareholders. Needham acted as passive bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 770,538 shares of common stock at the follow-on offering price to cover over-allotments. Ichor Holdings, Ltd. will not receive any proceeds from the offering.

  • Flexion Therapeutics, Inc. (NASDAQ: FLXN) is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis ("OA"). Flexion's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive intra-articular injections for knee OA annually.

    Flexion Therapeutics, Inc. issued $201.3 million 3.375% convertible senior notes due 2024 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The underwriters fully exercised their option to purchase an additional $26.25 million in aggregate principal amount of the Notes to cover overallotments. Needham & Company acted as a co-manager for this transaction. Flexion intends to use the net proceeds from the Notes offering for the commercialization and manufacture of ZilrettaTM (also known as FX006), if approved, product pipeline development, as well as working capital and general corporate purposes. Flexion may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses, technologies, products or assets.

  • ViXS Systems (TSX: VXS) is a pioneer and market leader in designing revolutionary media processing semiconductor solutions for video over IP streaming solutions, with more than 470 patents issued and pending worldwide, numerous industry awards for innovation, and over 33 million media processors shipped to date. ViXS is driving the transition to Ultra HD 4K across the entire content value chain by providing professional and consumer grade chipsets that support the new High Efficiency Video Coding (HEVC) standard up to Main 12 Profile, reducing bandwidth consumption by 50% while providing the depth of color and image clarity needed to take advantage of higher-resolution content. ViXS’ XCodePro 300 family is ideal for Ultra HD 4K infrastructure equipment, and the XCode 6000 family of system-on-chip (SoC) products achieve unprecedented levels of integration that enable manufacturers to create cost-effective consumer entertainment devices. ViXS is headquartered in Toronto, Canada with offices in Europe, Asia and North America. VIXS™, the ViXS® logo, XCode®, XCodePro™ and Xtensiv™ are trademarks and/or registered trademarks of ViXS. Other trademarks are the property of their respective owners.

    ViXS Systems (TSX: VXS), a pioneer and leader in media processing solutions, today announced that it has sold its legacy MoCA (Multimedia over Coaxial Alliance) business to MaxLinear, Inc. (NYSE:MXL), a leading provider of radio frequency (RF) and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, data center, metro, long-haul fiber networks, and wireless infrastructure. This divestiture will allow ViXS to focus on its core video business strategies, built around delivering best-in-class UHD/HDR solutions for the Consumer and Video Delivery market segments. ViXS plans to use the sale proceeds to improve its balance sheet and for working capital needed to support customers to achieve profitable growth. Needham & Company acted as exclusive financial advisor to ViXS Systems.

  • Synacor (Nasdaq: SYNC) is the trusted technology development, multiplatform services and revenue partner for video, internet and communications providers, device manufacturers, and enterprises. Synacor’s mission is to enable its customers to better engage with their consumers. Its customers use Synacor’s technology platforms and services to scale their businesses and extend their subscriber relationships. Synacor delivers managed portals, advertising solutions, email and collaboration platforms, end-to-end video solutions and cloud-based identity management.

    Synacor, Inc. raised $21.7 million in its follow-on offering at $3.50 per share. Needham acted as joint bookrunner on the transaction. The Company’s underwriters exercised their option to purchase an additional 427,846 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Synacor, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate an organization’s operational response to critical events in order to keep people safe and businesses running. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events such as IT outages or cyber-attacks, over 3,200 global customers rely on the company’s SaaS-based platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes, and track progress on executing response plans. The company’s platform sent over 1.5 billion messages in 2016, and offers the ability to reach more than 200 countries and territories with secure delivery to over 100 different communication devices. The company’s critical communications and enterprise safety applications, which include Mass Notification, Incident Management, IT Alerting, Safety Connection™, Community Engagement™, Secure Messaging, Visual Command Center and Crisis Commander, are easy-to-use and deploy, secure, highly scalable and reliable. Everbridge serves 8 of the 10 largest U.S. cities, 8 of the 10 largest U.S.-based investment banks, all four of the largest global accounting firms, 24 of the 25 busiest North American airports and 6 of the 10 largest global automakers. Everbridge is based in Boston and Los Angeles with additional offices in San Francisco, Lansing, Beijing, London and Stockholm.

    Everbridge, Inc. raised $73.8 million in its upsized follow-on offering consisting of both primary and secondary shares at $19.85 per share. Needham acted as co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 451,825 shares at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Everbridge, Inc. for for general corporate purposes, including working capital and capital expenditures. Everbridge will not receive any proceeds from the sale of shares sold by the selling stockholders.

  • GigPeak, Inc. (NYSE MKT:GIG) is a leading innovator of semiconductor ICs and software solutions for high-speed connectivity and high-quality video compression over the network and the cloud. The focus of the company is to develop and deliver products that enable lower power consumption and faster data connectivity, more efficient use of network infrastructure, broader connectivity to the cloud, and reduce the total cost of ownership of existing network pipes from the core to the end user. GigPeak addresses both the speed of data transmission and the amount of bandwidth the data consumes within the network, and provides solutions that increase the efficiency of the Internet of Things, leveraging its strength in high-speed connectivity and high-quality video compression. The extended product portfolio provides more flexibility to support changing market requirements from ICs and MMICs through full software programmability and cost-efficient custom ASICs.

    Gigipeak Inc., a manufacturer of semiconductor ICs and software solutions for high-speed connectivity and high-quality video compression over the Network and the Cloud, completed its previously announced sale to Integrated Device Technology (NASDAQ: IDTI), a global leader in mixed signal semiconductor solutions for the advanced communications, computing and consumer industries, for $3.08 per share in cash or approximately $250 million. The acquisition of GigPeak provides IDT with a highly regarded optical interconnect product and technology business that is complementary to IDT's leadership position in real-time interconnect products. Needham & Company acted as a financial advisor to GigPeak, Inc.

  • Essen BioScience, Inc. develops and manufactures instruments, software, reagents and consumables which enable researchers to remotely image and quantitate a wide variety of cellular processes over time. The IncuCyte® System, is a real-time quantitative live-cell analysis platform that enables visualization and quantification of cell behavior over time by automatically gathering and analyzing images around the clock within a standard laboratory incubator. The system allows researchers to make time-lapsed fully kinetic measurements from living cells over days and weeks thus providing insight into active biological processes in real time. The company was founded in Ann Arbor, Michigan in 1996.

    Essen BioScience Inc., a pioneer and leader in the field of cell-based assays and instrumentation used for life sciences research, completed its previously announced sale to Sartorius Group AG (FWB: SRT), a leading partner to the biopharmaceutical industry and laboratories, for $320 million. Through this acquisition, Sartorius will significantly expand its portfolio for bioanalytics, a field the company has recently entered via the IntelliCyt acquisition in 2016. Needham & Company acted as a financial advisor to Essen BioScience Inc.

  • Cara Therapeutics (NASDAQ: CARA) is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system and have demonstrated, in Phase 2 trials, preliminary efficacy in patients with moderate-to-severe pain and pruritus without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

    Cara Therapeutics, Inc. raised $92.12 million in its follow-on offering at $18.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 667,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Cara Therapeutics, Inc. to fund the company's clinical and research development activities, including the completion of the Phase 3 program for I.V. CR845 in uremic pruritus, two Phase 3 trials of I.V. CR845 in acute pain and a Phase 2b trial of oral CR845 in osteoarthritis pain, as well as for working capital and general corporate purposes.

  • Analogix Semiconductor, Inc. designs and manufactures semiconductors for the digital multimedia market, from portable devices such as smartphones to high-end graphics cards and large, high-definition displays. Analogix is the market leader in providing end-to-end interface connectivity semiconductor solutions for DisplayPort, including high-speed signal conditioners and the SlimPort family of products, and an industry leader in mobile display controllers, such as low-power, high-speed timing controller solutions. The DisplayPort standard is an innovative, packetized digital interface for high-resolution video and audio that was developed by the Video Electronics Standards Association (VESA). SlimPort branded products are compliant with DisplayPort, Mobility DisplayPort (MyDP), and DisplayPort Alternate Mode over the USB Type-C connector.

    Analogix Semiconductor, Inc., a global leader in designing high-performance mixed-signal semiconductors that enable “HD Everywhere,” the go-anywhere, any-mobile-to-any-screen, high-definition experience, completed its previously announced sale to Beijing Shanhai Capital Management Co, Ltd. (Shanhai Capital), a pioneer buyout fund in healthcare and technology managing RMB and USD-denominated funds. Enhanced by the strong financial support of its new investors, Analogix will continue building and growing the company into a global leader in high-performance semiconductors. Needham & Company acted as a financial advisor to Analogix Semiconductor, Inc.

  • Cryoport, Inc. (NASDAQ: CYRX) is the life sciences industry's most trusted global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.

    Cryoport, Inc. raised $12.7 million in its follow-on offering at $2.00 per share. Needham acted as joint-bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 825,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Cryoport, Inc. for business growth, including as working capital and for other general corporate purposes.

  • EVRYTHNG is the Internet of Things Smart Products Platform connecting consumer products to the Web and managing real-time data to drive applications and analytics throughout the product lifecycle.

    Evrythng completed the pricing of its $24.8 million Series B funding round led by San Francisco-based Sway Ventures and also including Toronto-based Generation Ventures and London-based Bloc Ventures. Needham acted as sole placement agent for this transaction. The new investors join a strong base of existing backers including: Cisco Investments, Samsung, BHLP, Atomico, Dawn Capital and Advance Vixeid Partners. The funding will support EVRYTHNG’s growth through partnerships, the expansion of its team and continued development of its enterprise-focused IoT platform for managing intelligent software identities in the cloud and digital lifecycle applications for product manufacturers.

  • AXT, Inc. (NASDAQ: AXTI) designs, develops, manufactures and distributes high-performance compound and single element semiconductor substrates comprising indium phosphide (InP), gallium arsenide (GaAs) and germanium (Ge) through its manufacturing facilities in Beijing, China. In addition, AXT maintains its sales, administration and customer service functions at its headquarters in Fremont, California. The company’s substrate products can be used primarily in fiber optic communications, 3-D sensing, solar cell, lighting display applications and wireless communications. Its vertical gradient freeze (VGF) technique for manufacturing semiconductor substrates provides significant benefits over other methods and enabled AXT to become a leading manufacturer of such substrates. AXT has manufacturing facilities in China and, as part of its supply chain strategy, has partial ownership in ten companies in China producing raw materials.

    AXT Technology, Inc. raised $34.5 million in its follow-on offering at $6.50 per share. Needham acted as the sole bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 692,307 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by AXT, Inc. for general corporate purposes, which may include the relocation of its gallium arsenide product line, working capital, capital expenditures and other corporate expenses.

  • Dermira, Inc. (NASDAQ: DERM) is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s product pipeline includes three Phase 3 product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate, in development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; and olumacostat glasaretil, in development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California.

    Dermira, Inc. raised $193.8 million in its upsized follow-on offering at $33.70 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 750,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dermira, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses. In addition, it will enable UCB to submit an sBLA to the FDA for potential approval of Cimzia; complete registration-enabling activities and submit an NDA to the FDA for potential approval related to glycopyrronium tosylate; enable the company to complete and generate topline results from their ongoing Phase 3 pivotal clinical trials for olumacostat glasaretil; commercialize their Cimzia and glycopyrronium tosylate product candidates assuming that the company receives the necessary regulatory approvals; complete registration-enabling activities and submit an NDA to the FDA for potential approval related to olumacostat glasaretil assuming the data from their Phase 3 clinical trials are positive; and commence potential lifecycle management activities related to their glycopyrronium tosylate and olumacostat glasaretil product candidates.

  • The Trade Desk, Inc. (NASDAQ:TTD) is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize more expressive data-driven digital advertising campaigns across ad formats, including display, video, audio, native and, social, on a multitude of devices, such as computers, mobile devices, and connected TV. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across the United States, Europe, and Asia.

    The Trade Desk, Inc. raised $258.5 million in its upsized follow-on offering at $35.50 per share of Class A common stock by certain selling stockholders . Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 949,798 shares of Class A common stock at the follow-on offering price to cover over-allotments. The Trade Desk will not receive any proceeds from the offering.

  • Athersys, Inc. (NASDAQ:ATHX) is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products.

    Athersys, Inc. raised $23.0 million in its follow-on offering at $1.01 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,970,300 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Athersys, Inc. for working capital and general corporate purposes, including funding towards its Phase 3 MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study-2 ("MASTERS-2") clinical study and its other ongoing clinical programs.

  • Applied Micro Circuits Corporation (NASDAQ: AMCC) is a global leader in computing andconnectivity solutions for next-generation cloud infrastructure and data centers. AppliedMicro delivers silicon solutions that dramatically lower total cost of ownership. Corporate headquarters are located in Sunnyvale, California. AppliedMicro became a wholly owned subsidiary of MACOM on 01/26/2017.

    Applied Micro Circuits Corporation (NASDAQ: AMCC), a global leader in computing and connectivity solutions, completed its previously announced sale to MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI), a leading supplier of high-performance RF, microwave, millimeterwave, and lightwave semiconductor products, for $764.9 million in the form of an exchange offer. Needham & Company acted as exclusive financial advisor to Applied Micro Circuits.

  • Kornit Digital (NASDAQ: KRNT) develops, manufactures and markets industrial digital printing technologies for the garment, apparel and textile industries. Kornit delivers complete solutions, including digital printing systems, inks, consumables, software and after-sales support. Leading the digital direct-to-garment printing market with its exclusive eco-friendly NeoPigment printing process, Kornit caters directly to the changing needs of the textile printing value chain. Kornit’s technology enables innovative business models based on web-to-print, on-demand and mass customization concepts. With its immense experience in the direct-to-garment market, Kornit also offers a revolutionary approach to the roll-to-roll textile printing industry: digitally printing with a single ink set onto multiple types of fabric with no additional finishing processes. Founded in 2003, Kornit Digital is a global company, headquartered in Israel with offices in the USA, Europe and Asia Pacific, and serves customers in more than 100 countries worldwide.

    Kornit Digital, Ltd. raised $142.3 million in its upsized follow-on offering public offering. Of the 7,500,000 ordinary shares, 2,000,000 of the shares are being offered by Kornit and 5,500,000 of the shares are being offered by shareholders of the company, substantially all by the company’s largest shareholder, Fortissimo Capital Fund II (Israel) LP at $16.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,125,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Kornit Digital for general corporate purposes. The Company will not receive any of the proceeds from the sale of shares being offered by the selling shareholders.

  • Exablox is the company reimagining storage. Exablox solves businesses’ runaway storage costs and information management nightmares by providing a cloud-managed, scale-out, object-based solution that is affordable and easy to use. OneBlox is an inclusive storage offering that combines an elegant hardware architecture and integrated, enterprise-grade software, including inline deduplication, continuous data protection and disaster recovery. Exablox’s innovative approach to storage has led to widespread customer traction across verticals including higher education, healthcare, insurance and the legal as well as Fortune 500 companies. As of January 19, 2017, Exablox Corporation operates as a subsidiary of StorageCraft Technology Corporation.

    Exablox Corporation, the award-winning company reimagining storage, completed its sale to StorageCraft, the intelligent recovery and backup company. StorageCraft Technology Corporation and Exablox Corporation joined forces to completely focus on helping businesses analyze, protect, and store their data. The new entity is the first company to bring together a new approach that recognizes the disappearing lines between primary and secondary storage as well as between data availability and data protection. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to Exablox Corporation.

  • Mediafly is an enterprise software company that has worked with some of the most respected global sales organizations. The Mediafly Evolved Selling Platform™ aligns with every sales training methodology and is a proven technology for helping field sales organizations deliver a dynamic, interactive, insightful buying experience that ties seamlessly back to CRM. For the third year in a row, Mediafly has been recognized by Inc. Magazine as one of the top 5000 fastest-growing private companies in the US. For more information, visit www.mediafly.com.

    Mediafly, a leading enterprise software company designed to help companies transform and evolve how they sell through the delivery of a perfect in-person selling experience, announced the closing of a $10 million growth capital investment from Boathouse Capital. This is the first outside institutional round for the company and will provide Mediafly with a financial partner to support industry leading product innovation to meet the growing demand for more effective sales tools from organizations around the world. As part of the transaction, Andy Jang, Vice President at Boathouse Capital, will be joining Mediafly's Board of Directors. Needham & Company acted as exclusive financial advisor to Mediafly on this transaction.

  • Ichor Holdings, Ltd. (NASDAQ: ICHR) is a leader in the design, engineering and manufacturing of critical fluid delivery subsystems for semiconductor capital equipment. Our primary offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. Our gas delivery subsystems deliver, monitor and control precise quantities of the specialized gases used in semiconductor manufacturing processes such as etch and deposition. Our chemical delivery subsystems precisely blend and dispense the reactive liquid chemistries used in semiconductor manufacturing processes such as electroplating and cleaning. We also manufacture certain components for internal use in fluid delivery systems and for direct sales to our customers. This vertically integrated portion of our business is primarily focused on metal and plastic parts that are used in gas and chemical systems, respectively.

    Ichor Holdings, Ltd. raised $60.84 million in its initial public offering at $9.00 per share. Needham acted as a passive bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 881,667 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Ichor Holdings to repay outstanding borrowings under their Credit Facilities and the remainder for general corporate purposes, including funding working capital, operating expenses and the selective pursuit of business development opportunities in their focus segment areas.

  • Impinj (NASDAQ:PI) is a leading provider of RAIN RFID solutions. The Impinj Platform connects billions of everyday items such as apparel, medical supplies, automobile parts, drivers’ licenses, food and luggage to applications such as inventory management, patient safety, asset tracking and item authentication, delivering real-time information to businesses about items they create, manage, transport and sell. The Impinj Platform wirelessly delivers information about these items’ unique identity, location and authenticity, or Item Intelligence™, to the digital world, which Impinj believes is the essence of the Internet of Things.

    Impinj, Inc. raised $109.2 million in its follow-on offering at $27.00 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 527,380 shares of common stock at the follow-on offering price to cover over-allotments. The number of shares sold in the offering included 1,527,380 shares sold by Impinj and 2,515,869 shares sold by certain selling stockholders. The net proceeds from the sale of the shares from the offering will be used by Impinj, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses. Impinj did not receive any proceeds from the sale of the shares by the selling stockholders.

  • TTM Technologies, Inc. (NASDAQ: TTMI) is a major global printed circuit board manufacturer, focusing on quick-turn and technologically advanced PCBs, backplane assemblies and electro-mechanical solutions. TTM stands for time-to-market, representing how TTM's time-critical, one-stop manufacturing services enable customers to shorten the time required to develop new products and bring them to market.

    TTM Technologies, Inc. raised $158.7 million in its follow-on offering of 12,000,000 shares of its common stock by its largest stockholder, Su Sih (BVI) Ltd. (the “Selling Stockholder”) at $11.50 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,800,000 shares of common stock at the follow-on offering price to cover over-allotments from the Selling Stockholder. The Selling Stockholder will receive all of the proceeds from the offering.

  • MSP Corporation is an instrumentation and equipment company creating products for scientific research and industrial applications. They are known worldwide for their expertise in micro- and nano-particles and their creative use in research and manufacturing. MSP is the world leader in cascade impactor technology with products serving the pharmaceutical and aerosol research markets, as well nano-particle generation and measurement technology serving the semiconductor device fabrication market. The company offers products through its distribution network worldwide. MSP Corporation was incorporated in 1985 and is based in Shoreview, Minnesota. As of November 9, 2016, MSP Corporation operates as a subsidiary of TSI Incorporated.

    MSP Group, an instrumentation and equipment company with an expertise in micro- and nano-particles and their creative use in research and manufacturing, completed its sale to TSI Incorporated, an industry leader in the design and production of precision instruments for measurements relating to aerosol science, air flow, health and safety, indoor air quality, fluid dynamics and biohazard detection. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to MSP Group.

  • The Chinese consortium of investors was comprised of Beijing-based IC design and solutions manufacturer Chipone Technology Co., Ltd ("Chipone") and its financial partner Beijing E-Town International Investment & Development Co., Ltd. ("E-Town Capital"). It focuses on technology, media and telecommunications, clean technology, semiconductors, and modern information service industry.

    A Chinese consortium comprised of Beijing-based IC design and solutions manufacturer Chipone Technology Co., Ltd ("Chipone") and its financial partner Beijing E-Town International Investment & Development Co., Ltd. ("E-Town Capital") announced that it has completed the acquisition of the Integrated Memory Logic Limited (iML) subsidiary of Exar Corporation (NYSE: EXAR), a leading supplier of analog mixed-signal semiconductor components and system solutions serving the industrial, high-end consumer and infrastructure markets, for a net purchase price of $136.0 million in cash. Needham & Company acted as exclusive financial advisor to the Chinese consortium.

  • Lavante, Inc. designs and develops a cloud-based supplier information management (SIM) and profit recovery system for Fortune 1000 companies. The company offers Lavante SIM, a transformational tool to manage and validate supplier profile automatically; Lavante Recovery, an on-demand recovery auditing solution; and Lavante Connect, a platform for connecting companies and suppliers. It serves hospitality, retail, entertainment, manufacturing, and medical industries. The company was formerly known as AuditSolutions Inc. and changed its name to Lavante, Inc. in April 2009. Lavante, Inc. was founded in 2001 and is based in San Jose, California. As of October 31, 2016, Lavante, Inc. operates as a subsidiary of PRGX USA, Inc.

    Lavante, Inc., a SaaS-based procure-to-pay (P2P) supplier information management (SIM) and recovery audit services firm, completed its sale to PRGX Global, Inc. (Nasdaq: PRGX), a global leader in Recovery Audit and Spend Analytics services. The terms of the transaction have not been publicly disclosed. Needham & Company acted as exclusive financial advisor to Lavante, Inc.

  • Theravance Biopharma, Inc. (NASDAQ: TBPH) is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma. For more information, please visit www.theravance.com.

    Theravance Biopharma, Inc. raised $115.1 million in its follow-on offering at $26.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 577,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Theravance Biopharma, Inc. for general corporate purposes, which may include, among other things, research activities, preclinical and clinical development of product candidates, manufacture of pre-clinical, clinical and commercial drug supplies, selling and marketing expenses, capital expenditures, working capital, general and administrative expenses and acquisitions of technology or drug candidates.

  • Theravance Biopharma, Inc. (NASDAQ: TBPH) is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma. For more information, please visit www.theravance.com.

    Theravance Biopharma, Inc. issued $230.0 million principal amount of Convertible Senior Notes due 2023. The Notes will be general unsecured obligations of the Company and will pay interest semi-annually on May 1 and November 1 of each year at a rate of 3.25% per year. The initial conversion rate of the Notes is 29.0276 ordinary shares per $1,000 principal amount of the Notes (which is equivalent to an initial conversion price of approximately $34.45 per share), and will be subject to adjustment upon the occurrence of certain events. The initial conversion price represents a conversion premium of approximately 32.5% over the sale price of ordinary shares sold in the Shares Offering. The Notes will mature on November 1, 2023, unless earlier repurchased or converted. The Notes will be convertible into ordinary shares of the Company at the then-applicable conversion rate until the close of business on the second business day immediately preceding the stated maturity date. The Notes will not be redeemable at the Company's option prior to maturity except in connection with certain changes in tax laws. Holders of the Notes will have the right to require the Company to repurchase all or any portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of certain fundamental change events. The underwriters fully exercised their option to purchase an additional $30 million in aggregate principal amount of debentures to cover overallotments. Needham & Company acted as a co-manager for this transaction. The Company intends to use the net proceeds of the offerings for general corporate purposes, which may include, among other things, research activities, preclinical and clinical development of product candidates, manufacture of pre-clinical, clinical and commercial drug supplies, selling and marketing expenses, capital expenditures, working capital, general and administrative expenses and acquisitions of technology or drug candidates.

  • Quantenna Communications, Inc. (NASDAQ: QNTA) is a provider of high-performance Wi-Fi solutions. Quantenna’s solutions combine semiconductor architecture with system-level software and cloud analytics with the goal of delivering the highest speed, broadest coverage, highest capacity, and most reliable performance. Quantenna’s solutions primarily serve the non-mobile device market.

    Quantenna Communications, Inc. raised $108.4 million in its initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters exercised their option to purchase an additional 75,466 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Quantenna Communications for general corporate purposes, including working capital, operating expenses and capital expenditures. The company may also use a portion of the net proceeds to acquire complementary businesses, products, services or technologies.

  • Collegium Pharmaceutical, Inc. (Nasdaq:COLL) is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

    Collegium Pharmaceutical, Inc. raised $92.0 million in its follow-on offering at $16.00 per share. Needham acted as a co-lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 750,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Collegium Pharmaceutical, Inc. for the continued commercialization of Xtampza; funding research and development efforts of its other product candidates; and working capital and general corporate purposes, which may include the acquisition or licensing of product candidates, technologies, compounds, other assets or complementary businesses.

  • Everspin Technologies (NASDAQ: MRAM) is the leading provider of MRAM solutions. Everspin’s MRAM solutions offer the persistence of non-volatile memory with the speed and endurance of random access memory (RAM), and enable the protection of mission critical data particularly in the event of power interruption or failure. Everspin’s MRAM solutions allow its customers in the industrial, automotive and transportation, and enterprise storage markets to design high performance, power efficient and reliable systems without the need for bulky batteries or capacitors. Everspin is the only provider of commercially available MRAM solutions and over the past eight years has shipped over 60 million MRAM units. For more information, visit www.everspin.com.

    Everspin Technologies raised $40.0 million in its initial public offering at $8.00 per share. Needham acted as a joint-bookrunner on the transaction. The net proceeds from the sale of the shares will be used by Everspin Technologies for are to obtain additional capital, to create a public market for our common stock and to facilitate future access to the public equity markets. The company expects to use the net proceeds received from this offering for working capital and other general corporate purposes, including an estimated payment of $8.5 million due to GLOBALFOUNDRIES in December 2016, research and development activities, sales and marketing activities and capital expenditures, to enhance existing and develop new products, expand our manufacturing capabilities and to fund growth.

  • Acacia Communications (NASDAQ: ACIA) develops, manufactures and sells high-speed coherent optical interconnect products that are designed to transform communications networks through improvements in performance, capacity and cost. By converting optical interconnect technology to a silicon-based technology, a process Acacia refers to as the “siliconization of optical interconnect,” Acacia is able to offer products that meet the needs of cloud and service provider customers in a simple, open, high-performance form factor that can be easily integrated in a cost-effective manner with existing network equipment.

    Acacia Communications, Inc. raised $450.0 million in its follow-on offering at $100.00 per share. The offering consists of 1,210,302 shares from Acacia Communications and 3,289,698 shares from certain existing stockholders. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Acacia Communications, Inc. for working capital and general corporate purposes. Acacia Communications will not receive any of the proceeds from any sale of shares by the selling stockholders.

  • Nutanix, Inc. (NASDAQ: NTNX) makes infrastructure invisible, elevating IT to focus on the applications and services that power their business. The Nutanix enterprise cloud platform leverages web-scale engineering and consumer-grade design to natively converge compute, virtualization and storage into a resilient, software-defined solution with rich machine intelligence. The result is predictable performance, cloud-like infrastructure consumption, robust security, and seamless application mobility for a broad range of enterprise applications.

    Nutanix, Inc. raised $273.61 million in its upsized initial public offering of Class A common stock at $16.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,230,500 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Nutanix, Inc. for general corporate purposes, including working capital, sales and marketing activities, research and development and general and administrative matters.

  • Sarepta Therapeutics (NASDAQ: SRPT) is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including EXONDYS 51, designed to skip exon 51 and approved under the accelerated approval pathway.

    Sarepta Therapeutics, Inc. raised $345.0 million in its follow-on offering at $59.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 753,138 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Sarepta Therapeutics, Inc. principally for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities including the potential licensing or acquisition of complementary products and technologies and other general corporate purposes.

  • Oclaro, Inc. (NASDAQ: OCLR) is a leader in optical components, modules and subsystems for the core optical, enterprise and data center markets. Leveraging more than three decades of laser technology innovation, photonics integration, and subsystem design, Oclaro's solutions are at the heart of the fast optical networks and high-speed interconnects driving the next wave of streaming video, cloud computing, voice over IP and other bandwidth-intensive and high-speed applications.

    Oclaro, Inc. raised $144.04 million in its upsized follow-on offering at $8.35 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 2,250,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Oclaro, Inc. for general corporate purposes, including working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses.

  • The Trade Desk, Inc. (NASDAQ: TTD) is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize more expressive data-driven digital advertising campaigns across ad formats, including display, video, audio, native and, social, on a multitude of devices, such as computers, mobile devices, and connected TV. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across the United States, Europe, and Asia.

    The Trade Desk, Inc. raised $96.6 million in its initial public offering of its Class A common stock at $18.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 700,000 shares of common stock at the initial public offering price to cover over-allotments. The Trade Desk will not receive any proceeds from the sale of shares by the selling stockholders.

  • Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP) is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. With a successful Phase 2 clinical trial completed in 2015, Aquinox initiated a Phase 3 trial in 2016 (LEADERSHIP 301) with AQX-1125 for treatment of IC/BPS. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.

    Aquinox Pharmaceuticals, Inc. raised $75.4 million in its follow-on offering at $12.25 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 802,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Aquinox Pharmaceuticals, Inc. to fund additional clinical development of AQX-1125 and to fund pre-commercial and market assessment activities, research and development costs to advance its pipeline of preclinical product candidates and for working capital and other general corporate purposes.

  • DFMSim provides advanced enabling software solutions to the global semiconductor industry. The company's technology simulates key IC design and processing steps to quickly find and avoid systemic defects that threaten yields and increase manufacturing costs. DFMSim's solutions are versatile, modular, easy to use and can be rapidly configured for various manufacturing processes and tools. Headquartered in Silicon Valley, the company maintains R&D, sales and support offices in multiple global locations.

    DFMSim Inc., a leader in chip simulation technology, completed its sale to Applied Materials (NASDAQ: AMAT), the global leader in providing innovative equipment, services and software to enable the manufacture of advanced semiconductor, flat panel display and solar photovoltaic products. The terms of the transaction have not been publicly disclosed. Needham & Company acted as the exclusive financial advisor to DFMSim Inc.

  • Inphi Corporation (NYSE: IPHI) is a leader in high-speed data movement. We move big data - fast, throughout the globe, between data centers, and inside data centers. Inphi's expertise in signal integrity results in reliable data delivery, at high speeds, over a variety of distances. As data volumes ramp exponentially due to video streaming, social media, cloud-based services, and wireless infrastructure, the need for speed has never been greater. That's where we come in. Customers rely on Inphi's solutions to develop and build out the Service Provider and Cloud infrastructures, and data centers of tomorrow.

    Inphi Corporation issued $287.5 million principal amount of Convertible Senior Notes due 2021 in an upsized transaction to qualified institutional buyers pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). Inphi will settle conversions of the notes by paying or delivering, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at its election. In addition, holders may require Inphi to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture governing the notes) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the repurchase date. The underwriters fully exercised their option to purchase an additional $37.5 million in aggregate principal amount of notes to cover over-allotments. Needham & Company acted as a co-manager for this transaction. Inphi intends to use a portion of the net proceeds from the offering of the notes to pay the cost of certain capped call transactions. Inphi intends to use the remainder of the net proceeds from the offering of the notes for general corporate purposes, including financing potential acquisitions and other strategic transactions.

  • EMC Corporation (NYSE:EMC) is a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service. Fundamental to this transformation is cloud computing. Through innovative products and services, EMC accelerates the journey to cloud computing, helping IT departments to store, manage, protect and analyze their most valuable asset – information – in a more agile, trusted and cost-efficient way.

    EMC Corporation (NYSE: EMC), a global leader in enabling businesses and service providers to transform their operations and deliver IT as a service, completed its historic previously announced sale to Dell Technologies, creating a unique family of businesses that provides the essential infrastructure for organizations to build their digital future, transform IT and protect their most important asset, information. This combination creates a $74 billion market leader with an expansive technology portfolio that solves complex problems for customers in the industry’s fast-growing areas of hybrid cloud, software-defined data center, converged infrastructure, platform-as-a-service, data analytics, mobility and cybersecurity. Under the terms of the transaction, EMC shareholders received $24.05 per share in cash in addition to tracking stock linked to a portion of EMC’s economic interest in the VMware business. Based on the estimated number of EMC shares outstanding at close, EMC shareholders received 0.11146 shares of new tracking stock (NYSE: DVMT) for each EMC share. It is the largest technology transaction on record and Dell Technologies now becomes the world’s largest privately-controlled technology company. Needham & Company acted as a financial advisor to EMC on this transaction.

  • Galvanize is a dynamic tech learning community that offers education, workspace and networking for students, startups and large companies. Galvanize teaches web development, data science and data engineering to students, offers support and workspace to over 700 member companies and provides over 200 networking events across nine urban campuses throughout the nation. Galvanize campuses bring together entrepreneurs, students, investors, mentors, and great people and companies to develop the skills, mindset and networks necessary to thrive in a technology driven world.

    Galvanize, Inc., a market leader delivering technology education programs and community workspaces, announced a $45 million Series B investment led by ABS Capital Partners, a leading late-stage growth company investor. Colorado Impact Fund, Haystack Partners, Greg Maffei, Aspen Grove Capital and existing investor University Ventures also participated. Needham acted as financial advisor and sole agent to Galvanize on this transaction. The funding will be used to provide more students access to Galvanize’s modern web development and data science programs and directly address employer’s needs to re-skill existing employees. As a result of the financing, Paul Mariani, a general partner with ABS Capital, will join the Galvanize Board of Directors.

  • ACADIA Pharmaceuticals, Inc (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

    ACADIA Pharmaceuticals, Inc. raised $230.0 million in its follow-on offering at $33.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 909,090 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals, Inc. for to fund commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin, and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and sales, general and administrative expenses. The company may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.

  • Digimarc Corporation (NASDAQ: DMRC), based in Beaverton, Oregon, is the inventor of the Digimarc Discover® platform featuring the imperceptible Digimarc Barcode for automatically identifying and interacting with virtually any media. Digimarc owns an extensive intellectual property portfolio, with patents in digital watermarking, content identification and management, media object discovery, and intuitive computing more generally.

    Digimarc, Inc. raised $42.5 million in its upsized follow-on offering at $30.00 per share. Needham acted as the joint bookrunner on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 185,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Digimarc, Inc. for for general working capital purposes as well as to accelerate the Company’s growth initiatives. These growth initiatives include increasing sales, marketing and operations resources for global expansion; supporting a growing supplier network, and feasibility and pilot projects with prospective customers; continuing development of tools and processes to support efficient, effective and timely implementation of its technology; and further research and intellectual property development.

  • UnboundID provides the industry’s leading software platform for customer identity and access management. Enterprise customers select the UnboundID Platform to modernize traditional Identity and Access Management systems, and enable new customer-facing digital business initiatives that provide real-time personalization and delivery of a consistent customer experience across channels and devices. Some of the world’s largest and most demanding companies in financial services, retail, hospitality, telecommunications and healthcare rely on UnboundID to manage and protect their identity and preference data across application portfolios and systems of engagement. UnboundID customers consistently report a total cost of ownership savings between 25 to 90 percent relative to legacy directory servers, and the company enjoys a 100% customer renewal rate.

    UnboundID, a market leading provider of customer identity and access management software, to help enterprises improve customer engagement, completed its sale to Ping Identity, the leader in Identity Defined Security. Terms of the transaction were not disclosed. The deal puts Ping Identity, which is owned by Vista Equity Partners, firmly in at the intersection of identity and customer engagement and management. The combined company provides Identity and Access Management solutions for the world’s leading companies, including over half of the Fortune 100, and manages over 3 billion identities. Needham & Company acted as the exclusive financial advisor to UnboundID.

  • Ellie Mae, Inc. (NYSE:ELLI) is a leading provider of innovative on-demand software solutions and services for the residential mortgage industry. Mortgage lenders of all sizes use Ellie Mae’s Encompass® all-in-one mortgage management solution, Mavent Compliance Service, and AllRegs research, reference and education resources to improve compliance, loan quality and efficiency across the entire mortgage lifecycle.

    Ellie Mae, Inc. raised $284.63 million in its follow-on offering at $90.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 412,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Ellie Mae, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

  • Argos Therapeutics (NASDAQ: ARGS) is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients.

    Argos Therapeutics, Inc. raised $50.0 million in its follow-on offering at $5.50 per share of common stock and accompanying warrants . Needham acted as the lead manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by Argos Therapeutics, Inc. to fund their pivotal Phase 3 ADAPT trial of AGS-003, the ongoing and planned investigator-initiated Phase 2 clinical trials of AGS-003, their share of the expected costs of the leasing, build-out and equipping of a commercial manufacturing facility and activities in preparation for the submission of a BLA to the FDA for AGS-003, and for working capital and other general corporate purposes.

  • Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.

    Nicox S.A. completed the pricing of an offering a reserved capital increase of ordinary shares of the Company to a specific category of investors. The gross proceeds of the financing are approximately €18 million, for a total of 2,064,000 million new shares. Needham acted as lead placement agent for this transaction. The net proceeds from the sale of the Units will be used by Nicox S.A. for clinical development of pipeline candidates (NCX 4251 in blepharitis and NCX 470 in glaucoma), working capital and general corporate purposes.

  • Impinj (NASDAQ: PI) is a leading provider of RAIN RFID solutions. The Impinj Platform connects billions of everyday items such as apparel, medical supplies, automobile parts, drivers’ licenses, food and luggage to applications such as inventory management, patient safety, asset tracking and item authentication, delivering real-time information to businesses about items they create, manage, transport and sell. The Impinj Platform wirelessly delivers information about these items’ unique identity, location and authenticity, or Item Intelligence™, to the digital world, which Impinj believes is the essence of the Internet of Things.

    Impinj, Inc. raised $77.3 million in its upsized initial public offering at $14.00 per share. Needham acted as a lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 720,000 shares of common stock at the initial public offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Impinj, Inc. to repay $5.0 million of indebtedness under the mezzanine credit facility and the remainder will be used for working capital and other general corporate purposes.

  • FormFactor, Inc. (NASDAQ: FORM) helps semiconductor manufacturers test the integrated circuits (ICs) that power consumer mobile devices, as well as computing, automotive and other applications. The company is one of the world’s leading providers of essential wafer test technologies and expertise, with an extensive portfolio of high-performance probe cards for DRAM, Flash and SoC devices. Customers use FormFactor’s products and services to lower overall production costs, improve their yields and enable complex next-generation ICs. Headquartered in Livermore, California, the company services its customers from a network of facilities in Europe, Asia and North America.

    FormFactor, Inc. (Nasdaq:FORM) announced that it has completed the acquisition of Cascade Microtech, Inc. (NASDAQ: CSCD),a worldwide leader in precision contact, electrical measurement and test of integrated circuits (ICs), optical devices and other small structures, for a net purchase price of $352 million in cash and stock. Needham & Company acted as the exclusive financial advisor and provided a fairness opinion to the Board of Directors of FormFactor, Inc. as part of its services.